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Telomerase is a ribonucleoprotein that is reactivated in cancer cells to allow for 
continuous cellular division and indefinite growth. With telomerase being expressed in 
more than 85% of all cancer, it is imperative that we understand how to selectively 
inactivate and degrade this unique DNA polymerase. In doing so, we can specifically 
target tumor cells to erode their telomeres so that they will undergo apoptosis or 
senescence. Through this research, we have learned that telomerase can be degraded in 
the nucleoplasm by Hsp90 chaperone inhibition and in the cytoplasm by the dominant 
negative mutant, D712A V713I. These findings should guide future drug design to target 
sites on telomerase that interact with Hsp90 and catalytic divalent metal ions. 
Previous studies have shown that chaperones function to stabilize the RNP and 
that their inhibition results in ubiquitin-mediated degradation. However, a detailed 
understanding of how telomerase is signaled for degradation is not well defined. We 
 ix
showed that Hsp90 inhibition causes telomerase to be degraded by a nuclear 
ubiquitin/proteasome pathway such that exportation to the cytoplasm is not required. 
Using  confocal fluorescence microscopy and immunoprecipitation /Western analysis, we 
showed that nucleoplasmic GFP-hTERT is ubiquinated and degraded within 2 hrs of 
exposure to the Hsp90 inhibitor, Radicicol. Upon combined treatment with the 
proteasome inhibitor, MG132, degradation is inhibited as shown by Western analysis and 
fluorescent intensity. Additionally, fluorescent pattern with inhibition of degradation 
shows telomerase aggregation and co-localization with the nuclear proteasome and not 
with nucleoli. However, the combined treatment with the exportin inhibitor, Leptomycin 
B, resulted in complete loss of fluorescence. Taken together, these data suggest that 
Hsp90 inhibition causes telomerase to immediately undergo nuclear degradation, which 
may function in the nuclear quality-control of telomerase.   
The dominant negative expression of telomerase has been shown by many 
investigators to cause shortening of telomeres. However, the mechanism of how it 
functions and its fate inside the cell are still unknown. After stably expressing the wild-
type and dominant negative mutants GFPhTERT in cells, we show that the D712A V713I 
mutation causes the ubiquination and degradation of the mutant and wild-type hTERT 
which eventually leads to the shortening of telomeres. Degradation appears to be 
cytoplasmic since the additional mutation for the nuclear export signal (nes) and 
treatment with the exportation inhibitor are able to prevent the reduction in protein levels 
and fluorescence. Based on this cytoplasmic degradation and the additional co-
localization of the GFPDNhTERT to the nucleoli, we propose two new mechanisms of 
dominant negative hTERT utilizing the theory of interactive dimerization. First, the 
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heterodimer of DNhTERT : wt hTERT may be degraded at a faster rate than the wt 
hTERT homodimer. Second, the heterodimer may be sequestered in the nucleoli thus 
diminishing the wild-type hTERT access to the telomere in the nucleoplasm.  
Overall, we have shown that telomerase can be degraded in the nucleoplasm or 
cytoplasm depending on the mechanism of inhibition. The significance of this is a better 
understanding of how Hsp90 inhibition and dominant negative hTERT expression cause 
the degradation of wild-type hTERT. We have also suggested potential mechanisms of 
dominant-negative hTERT effect and resistance. With this knowledge, future drug 
therapies can be designed based on these inhibitors to not only inactivate but also to 
cause the degradation of an enzyme that is crucially important for the immortalization of 
cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 1 
Background and Review of the Literature 
 
 
Cancer and Telomeres 
According to the American Cancer Society, about 1,500 Americans die from 
cancer every day. It is the second leading cause of death behind heart disease. These 
statistics justify the need for ongoing research to better understand and treat this 
devastating disease. Cancer is currently viewed as an accumulation of acquired and 
inherited genetic defects resulting in the uncontrollable and continuous growth of 
aberrant cells in a person’s body. Visually, cancer is a complex tissue composed of the 
cancer cells interacting with the extracellular matrix, fibroblast, endothelial and immune 
cells (Hanahan and Weinberg 2000). Many molecular characteristics of cancer have been 
delineated but they all share six common features: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death, tissue 
invasion or metastasis, sustained angiogenesis, and limitless replicative potential 
(Hanahan and Weinberg 2000). The inhibition of this last feature of unlimited 
proliferation by induction of a telomere maintenance mechanism holds great potential as 
a highly selective and nearly universal cancer therapeutic approach. 
Telomeres are repetitive DNA sequences with bound proteins at the ends of linear 
chromosomes, serving as a mitotic clock and a reservoir for DNA loss during replication. 
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For homo sapiens, the telomeres of young somatic cells are 15-18 Kb of the repetitive 
sequence, TTAGGG (Kipling and Cooke 1990). Telomere-specific proteins such as 
TRF1, TRF2, POT1, Rap1, TPP1 and TIN2 collectively known as shelterin, regulate the 
length and protect chromosomes ends from being recognized as damaged DNA (de 
Lange 2005; Cristofari et al. 2007). Additional layers of protection may include the intra-
telomeric formation of a T-loop based on the strand invasion by the G-rich overhang 
(Griffith et al. 1999) and possibly a G-quadruplex structure (Tsai et al. 2007). Several 
non-telomere specific proteins such as WRN, BLM, ERCC1/XPF, PARP-2, Tankyrase, 
Rad51D, Ku, DNA-PKcs, and MRN complex, have been shown to associate with the 
telomere and serve various DNA repair functions (de Lange 2005). With each cell 
division, 20-200 bp of telomeric DNA is lost due to the end replication problem (Figure 
1), the inability of eukaryotic cells to replicate the extreme 3’ terminal overhang of the 
lagging strand (Harley et al. 1990; Hastie et al. 1990; Lindsey et al. 1991). The 3’ 
overhang can vary in length from 24 bp to over 400 bp (Cimino-Reale et al. 2001) and in 
the last nucleotide (Sfeir et al. 2005). After approximately 50-60 cell divisions, the 
telomeres become critically short (Harley et al. 1990), causing most human somatic cells 
to undergo replicative senescence.  
Normally, this permanent growth arrest is an in vivo mechanism for cells to 
prevent transformation into cancer. However, according to a telomere-based cancer 
model (Figure 2), if a cell acquires a mutation resulting in the inhibition of DNA damage 
checkpoint proteins such as p53 or pRb then the cell can bypass senescence (Mortality 
stage 1 or M1) and continue to grow. In doing so, the pre-cancerous cells can acquire  
35’ 
3’
5’
3’
Lagging strand
Leading strand
RNA primers 
removed
Unreplicated 3’ 
overhang
Figure 1. The End Replication Problem. Continuous DNA replication can 
occur on the leading strand. The lagging strand’s discontinuous method results in 
unreplicated 3’ overhang when the RNA primer is removed and degraded. With 
each cellular division, this 3’ overhang is lost thus causing the gradual telomere 
erosion. Adapted from White et al., 2001
4or pRb or p16/Ink4a
by telomerase or ALT pathway 
Figure 2. Telomere model for the immortalization of pre-cancerous cells.
Normally, cells undergo permanent growth arrest or senescence after telomeres 
reach a certain length. This Mortality Stage 1 or M1 can be overcome if the cell 
acquires defects in p53, pRB or p16. Continued growth causes telomeres to reach 
a critical length in which the pre-cancerous cells undergo crisis or mortality stage 
2 or M2. The rare cells that survive have activated a telomere maintenance 
(telomerase or ALT) pathway through the mechanisms of genomic instability. 
Adapted from Shay and Wright, 2001.  
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more changes in growth and rest signals, i.e. activation of ras or inhibition of p16. The 
order and variety of these molecular changes may vary with each individual cancer. 
During this extended lifespan process, the telomeres continue to shorten to a critical point 
such that the cells undergo crisis (Mortality stage 2 or M2) and apoptosis. These 
extremely short telomeres begin a process of fusion-breakage bridge cycles that allow 
chromosomes’ ends to fuse then break during mitosis, thus forming the multitude of 
chromosomal abnormalities, gene amplification and deletions observed in cancer. The 
pre-cancerous cells that survive must activate telomerase or the alternative telomere 
maintenance (ALT) pathway through the various mechanisms of genomic instability. 
.  
Telomerase  
Telomerase is a unique DNA polymerase that adds telomeric repeats onto the 3’ 
overhang of the lagging strand by reverse transcription (Figure 3A) (Morin 1989; Lingner 
et al. 1997; Makarov et al. 1997; McElligott and Wellinger 1997; Wright et al. 1997; 
Huffman et al. 2000), allowing conventional DNA polymerases to replicate further out on 
the linear chromosome. The human telomerase RNP minimally consists of 2 parts: the 
RNA component, hTR or human Telomerase RNA (Feng et al. 1995) and the catalytic 
protein subunit, hTERT or human TElomerase Reverse Transcriptase (Kilian et al. 1997; 
Meyerson et al. 1997; Nakamura et al. 1997). The hTR gene is located on 3q26 
(Parkinson et al. 1997) and is constituitively transcribed in nearly all cell types (Feng et 
al. 1995). hTR has an 11 bp region near its 5’ end that serves as a template for the 
addition of TTAGGG repeats. hTERT is the most distal gene on chromosome 5, located  
6A
hTR
CAAUCCCAAUC
5’TTAGGGTTAGGGTTAGGGTTAG
3’AATCCC
5’
3’
hTERT
Telomere
B
Figure 3. Model of telomerase holoenzyme adding telomeric repeats onto the 
3’ overhang during the elongation step. A. hTERT utilizes hTR’s template to 
reverse transcribes the telomeric repeats GGTTAG onto the 3’ overhang which 
can vary in length and in the last nucleotide. B. Translocation to the other 
template occurs so that the process can be repeated. Courtesy of Wenz et al., 
2001.
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at 5p15 (Bryce et al. 2000) which may implicate its feedback involvement in the 
telomeric position effect whereby longer telomeres reduce expression of distal genes 
(Baur et al. 2001). hTERT is transcribed and spliced into several variants, which may 
compete with full length transcript to regulate activity during development and 
tumorigenesis (Yi et al. 2000). hTERT is a 127 kD protein that can be divided into four 
regions: N-terminal, hTR binding, reverse transcriptase and C-terminal domains. In 
contrast to the expression of hTR, hTERT is only expressed in cells with increased or 
unlimited proliferative potential, while transcriptionally silent in most somatic cells 
(Ducrest et al. 2001). hTERT is expressed in hematopoietic stem cells, activated 
lymphocytes, epidermal basal cells, endometrium, intestinal crypt cells (Wright et al. 
1996), and more than 85% of all human cancers (Kim et al. 1994; Shay and Bacchetti 
1997).  
Direct evidence shows that ectopic hTERT expression is sufficient to extend the 
lifespan of many somatic cell types by telomere maintenance or elongation (Bodnar et al. 
1998), implicating telomere erosion as a primary mechanism of replicative senescence. In 
addition, ectopic hTERT expression in combination with two oncogenes (SV40 large T 
antigen and Ras) resulted in the direct tumorigenic conversion of normal human epithelial 
and fibroblast cells (Hahn et al. 1999). Conversely, inhibition of telomerase limits the 
growth of tumorgenic cell lines by inducing apoptosis or senescence (Hahn et al. 1999). 
Mice with double knockouts of the RNA component of telomerase, mTR, and the tumor 
suppressor gene, INK4a, showed impaired tumor development, supporting the notion that 
telomerase is a necessary component in tumor cell growth in vivo (Greenberg et al. 1999). 
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Taken together, these findings strongly indicate that hTERT is the rate-limiting 
component that endows cells with telomerase activity, telomere maintenance, and 
continuous proliferation. 
Before assembly, hTERT and hTR are known to individually associate with a 
number of proteins. Pre-assembled hTERT is bound to the chaperone complex of hsp70, 
hsp40, hsp90 and p23 for folding (Holt et al. 1999) and maybe for maintaining a structure 
capable of assembly with hTR (Forsythe et al. 2001). hTR utilizes the following proteins 
for stability, maturation and localization: dyskerin, L22, hStau, La, hRNPC1/C2, hNHP2, 
hGAR1, and hNOP10 (Mergny et al. 2002). It is unknown as to where the telomerase 
ribonucleoprotein is assembled, but there is some evidence that it may occur in the 
nucleolus (Etheridge et al. 2002; Yang et al. 2002). After assembly, telomerase is stably 
complexed with chaperones, hsp90 and p23 (Forsythe et al. 2001), a non-functional TEP1 
(Liu et al. 2000) or dyskerin (Cohen et al. 2007). Several authors have proposed that the 
telomerase holoenzyme exists as a dimer composed of 2 hTERT and 2 hTR with 
functional interaction between the monomers (Figure 3B) (Beattie et al. 2001; Wenz et al. 
2001; Arai et al. 2002; Moriarty et al. 2002; Ly et al. 2003; Moriarty et al. 2004). 
 The crystal structure of hTERT and hTR have not been solved, but there are 
preliminary data to suggest how each may be constructed. The secondary structure of 
vertebrate telomerase RNA consists of four domains: pseudoknot, CR4-CR5, CR7, and 
BoxH/ACA that are composed of eight conserved regions (Chen et al. 2000). The 
domains are linked by variable regions that form single strands, loops and double helices. 
This predicted secondary structure for vertebrates is similar to previous work for ciliates. 
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On the other hand, the crystal structure of two domains of the catalytic component from 
Tetrahymena thermophila was recently solved. Telomerase Essential N-terminal (TEN) 
domain shows the ability to bind in a non-sequence specific manner to the RNA 
component, as well as a sequence specific binding to the telomeric DNA (Jacobs et al. 
2006). TEN also has a novel protein fold that forms a conserved groove containing 
critical amino acid residues for catalytic activity. The RNA binding domain lies between 
the N-terminal domain and the reverse transcriptase motifs and is composed mostly of 
alpha helices. The CP and T motifs form an extended pocket or groove that can bind 
single and double stranded RNA (Rouda and Skordalakes 2007). Overall, the quest to 
obtain the tertiary and quaternary structure of telomerase has been very challenging even 
with all of the resources applied, but the techniques used to obtain these Tetrahymena 
structures may help to achieve the ultimate goal. 
 
Alternative Lengthening of Telomeres 
Some human tumor cells and immortalized cell lines are able to maintain their 
telomeres without telomerase by the alternative lengthening of telomeres (ALT) pathway. 
These ALT cells have a wide bell curve distribution (1-50 Kb) of telomeric repeats that 
can rapidly increase or decrease by several kilobases after one cell cycle, as compared to 
telomerase-expressing tumor cells with relatively stable telomeric repeats (3-7 Kb), 
suggesting that ALT cells might have a recombination mechanism of maintaining 
telomeres. (Murnane et al. 1994; Bryan et al. 1995; Bryan et al. 1997; Park et al. 1998). 
Another common characteristic to all ALT cells is the presence of nuclear structures 
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called ALT-associated PML bodies (APBs). APBs have been found through co-
localization studies to contain telomeric DNA, TRF1, TRF2, and various proteins 
involved in DNA recombination: MRE11, RAD 50, NBS1, RAD 51, RAD 52, RPA, 
BLM and WRN. (Yeager et al. 1999; Wu et al. 2000; Henson et al. 2002). Initial 
evidence for the ALT mechanism came from yeast cells with inactivated telomerase 
being dependent on several proteins involved in homologous recombination such as RAD 
50, 51, 52 for survival (Le et al. 1999). In addition, human ALT cells showed evidence of 
inter-telomeric recombination by having a progressive increase in the number of tagged 
telomeres with increasing population doubling (Dunham et al. 2000). Overall, these data 
suggest that ALT cells employ homologous recombination to maintain telomeres and 
allow a small percentage of tumor cells to be immortalized.  
 
Telomerase-based Cancer Therapy  
Approximately 85-90% of all cancers utilize telomerase to maintain telomeres, 
making it a nearly universal marker and target for different types of cancer (Kim et al. 
1994). The field of telomerase-based cancer therapy has expanded rapidly over the years 
(White et al. 2001; Komata et al. 2002; Mergny et al. 2002; Shay and Wright 2002). Anti-
telomerase cancer therapies can be divided into two main categories: those that target 
telomerase directly and those that takes advantage of telomerase’s expression pattern. 
Direct inhibition of hTR or hTERT such as small molecule inhibitors, antisense, RNAi, 
and ribozymes should cause an immediate decrease in enzymatic activity. However, there 
is a disadvantage of delayed cellular senescence and apoptosis due to the time required to 
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shorten telomeres to critical lengths. Therapies based on expression such as hTERT 
promoter-suicide gene constructs and hTERT immunogens have the advantage of directly 
killing hTERT-expressing tumor cells. With any form of therapy, the issues of resistance 
and safety need to be considered. 
The inhibition of telomerase could lead to selection of resistant cells that maintain 
telomeres via the ALT pathway or more likely the upregulation of endogenous 
telomerase. Conversion of tumor cells to this alternative pathway after inhibition of 
telomerase has been observed in cell culture and mouse model. (Bechter et al. 2004) 
showed that a human colon cancer cell line with a mismatch repair defect activated the 
ALT mechanism after inhibition with a dominant-negative telomerase. (Chang et al. 
2003) demonstrated the possibility of conversion in a mouse model that had a double 
homozygous knockout of Ink4a/Arf and mTR, the mouse RNA subunit of telomerase. 
Activation of the ALT pathway occurred after a second round of in vivo selection and 
resulted in an aggressive tumor with less metastatic potential. Even though these 
conversion events can occur, the possibility is minimal since the inhibition would have to 
be a complete knockdown or knockout of telomerase. A much more likely scenario is the 
upregulation of endogenous telomerase in response to the shortening telomeres 
(Sachsinger et al. 2001; Delhommeau et al. 2002). This increase in endogenous mRNA 
levels could be due to a feedback to transcriptional factors or gene amplification (Zhang 
et al. 2000). Resistance can be minimized if anti-telomerase therapy is part of a 
combination including tumor debulking, traditional chemotherapy, radiation, and/or other 
novel cancer therapies.  
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Another potential limitation with telomerase-based therapy is that it could target 
cells that normally express hTERT such as lymphocytes, germ cells and stem cells 
(Figure 4). Because these cells have much longer telomeres and slower growth rates than 
cancer cells, it is expected that inhibition of telomerase will cause telomeres of cancer 
cells to reach critically short lengths more rapidly. After reduction or elimination of 
tumor burden, withdrawal of the inhibition should allow for recovery of the telomeres 
(Herbert et al. 1999). Phase I clinical trial of GRN163L, an antisense oligonucleotide 
conjugated to a lipid moiety and directed at the hTR template, will begin to address this 
biosafety issue (Herbert et al. 2002; Herbert et al. 2005). For hTERT immunotherapy, the 
possibility could be more lethal in terms of a triggered autoimmune response. In Phase I 
clinical trials, preliminary findings show no evidence of bone marrow toxicity 
(Vonderheide 2002) nor any clinical signs of autoimmune pathology (Su et al. 2005). 
However, more tests need to be conducted before safety concerns can be put to rest. 
Most telomerase-based therapies have been directed at the catalytic site of hTERT 
or template region of hTR. One category of telomerase-based therapy has taken 
advantage of the unique transcriptional control of hTERT by placing the hTERT 
promoter in front of a gene involved in converting a pro-drug into a toxic drug. Only cells 
expressing endogenous telomerase along with the drug converting enzyme would be 
killed. No therapy has been developed that focuses on the post-translational regulation of 
telomerase except for Hsp90 inhibition by a geldanamycin analog. If the tertiary structure 
of hTERT becomes revealed, then rational drug design could someday be directed at sites 
on telomerase that are involved in its post-translational regulation such as intracellular
13
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Figure 4. Effect of telomerase inhibition on telomere length in various cells.
Upon inhibition, telomeres should erode in cells that utilize telomerase to 
maintain its telomeres. However, telomeres of spermatogoonia and stem cells are 
expected to erode at a slower rate than cancer cells because of their slower 
growth rate. In addition, these cells have longer telomeres than cancer cells that 
will reach the critical length faster and undergo growth arrest or apoptosis. 
Removal of inhibition after a clinal response to cancer treatment should allow 
for the recovery of the spermatogoonia and stem cell telomere. Courtesy of 
White et al, 2001.
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 trafficking, phosphorylation, assembly, metal ion cofactor catalysis and ubiquination 
/degradation (Liu 2001) (Figure 5). After addressing these regulations, we will focus on 
the inhibition of assembly and induction of degradation by Hsp90 inhibition. This will be 
followed by the inhibition of cation catalysis, which may be part of the mechanism(s) for 
the dominant-negative hTERT. 
 
Intracellular trafficking 
The regulation of telomerase exportation involves 2 proteins, exportin or CRM1 
and 14-3-3σ (Figure 6). Telomerase has a nuclear export signal (NES) and a binding site 
for 14-3-3σ that are both located in the C-terminus (Seimiya et al. 2000). The NES 
consists of three leucine residues, which if mutated do not allow hTERT to bind Exportin 
or CRM1, causing telomerase to remain in the nucleus. CRM1 binding to the NES is 
regulated by 14-3-3σ binding to three serine/threonine residues that are located just 
downstream. Mutation of the 14-3-3σ binding site results in telomerase being more easily 
bound to CRM1, thus being translocated to the cytoplasm. Recently, a recombinant 
fungal immunomodulatory protein, reFIP-gts, was shown to inhibit telomerase activity 
(Liao et al. 2007). Its mechanism may involve endoplasmic reticulum localization and 
stress, thereby causing the release of intracellular Calcium ions resulting in the export and 
degradation of telomerase. Leptomycin B, an inhibitor of CRM1, and MG132, an 
inhibitor of proteasome were able to prevent the exportation of telomerase. Another 
exportation inducer of telomerase involves oxidative stress.(Haendeler et al. 2003)) 
showed that hydrogen peroxide or endogenous oxidative stress causes exportation of  
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Nucleolar
Localization 
Signal
MKRN1
N-terminal RNA binding Reverse transcriptase C-terminal
T
Figure 5. Post-translational regulation of telomerase. The nucleolar
localization signal is located at the N-terminus, whereas the nucleolar
localization region resides in the RNA binding domain. Phosphorylation is 
predicted to occur in the RNA binding domain by c-Abl with its SH3 binding, 
PKB (Akt) and PKC. The only known phosphorylation site is at Tyrosine 707 in 
Motif A of the reverse transcription domain. Nuclear exportation is governed by 
CRM1 binding to the nuclear export signal and 14-3-3sigma binding to its signal 
in the C-terminus. Ubiquination by MKRN1 occurs at unknown Lysine 
residue(s) from 946-1132 in the C-terminus. Adapted from Liu et al, 2001
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Figure 6. Regulation of telomerase exportation. hTERT is retained in the 
nucleus if it is bound to 14-3-3. If this region is unmasked then CRM1 is allowed 
to bind and export hTERT. The nuclear localization signal is unknown as well as 
its regulatory mechanism. The fate of telomerase after exportation is unknown but 
may involve refolding or degradation. Courtesy of Liu, 2001.
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telomerase via a CRM1 RanGTPase pathway, suggesting that nuclear exportation is a 
mechanism to reduce the anti-apoptotic activity of telomerase. 
Nucleolar localization signal has been assigned to two regions of telomerase. The 
N-terminus of hTERT contains four Arginines starting at amino acid #3 that serves as the 
nucleolar targeting signal (Yang et al. 2002). In addition, hTERT mutated for these four 
Arginines could not bind hTR and caused a decrease in telomere length, suggesting that 
telomerase is assembled in the nucleolus and that hTERT alone can have a dominant- 
negative effect. The second region that overlaps with the hTR binding domain, 
specifically with domain II and the T motif, may function to regulate the N-terminal 
Arginines (Etheridge et al. 2002). Besides assembly, the nucleolus has been proposed to 
serve as a sequestering destination for cells to regulate telomerase access to the telomeres 
by a cell cycle dependent release during S phase (Wong et al. 2002). The process of 
carcinogenesis allows cancer cells to retain telomerase in the nucleoplasm throughout the 
cell cycle so that telomeres may be maintained continuously. However, cancer cells can 
still sequester telomerase to the nucleolus if exposed to irradiation or other DNA 
damaging agents, which is hypothesized to prevent the de novo synthesis of telomeres on 
double strand breaks.  
The nuclear localization signal for telomerase has not been discovered. Several 
groups have shown different fragments of hTERT fused to a fluorescent protein 
remaining localized to the nucleus (Yang et al. 2002); (Etheridge et al. 2002). This is 
perplexing at first but is explainable since several proteins have been shown to contain 
two to three nuclear localization signals such as p53 (Shaulsky et al. 1990) and ribosomal 
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S6 (Schmidt et al. 1995). The purpose may be to ensure nuclear translocation if one 
signal is masked by interaction with another protein. Based on the PredictNLS and 
PSORT II internet servers, our analysis of the telomerase peptide sequence revealed 
several potential nuclear localization signal with positively charged Arginine and Lysine 
residues: a.a. 222 – RRRGGSASRSLPLPKRPRR bipartide, a.a. 485 – RRFLRNTKK, 
a.a. 643 – RTFRREKR and a.a. 968 – RNMRRK. It would be necessary to mutate all 3 or 
4 of these sites in order to prove that these are the nuclear localization signals. Only one 
paper has proposed a nuclear localization mechanism. (Akiyama et al. 2004) suggested 
that TNFα modulates the telomerase activity by inducing the translocation of hTERT 
bound NF-κB from the cytoplasm to the nucleus. Without TNFα exposure, the multiple 
myeloma cells used in this study has telomerase localized to the cytoplasm, which is 
contrary to other studies showing hTERT constitutively located in the nucleus of 
immortalized and cancer cells. With this discrepancy, the mechanism of telomerase 
nuclear localization needs to be further evaluated. 
 
Phosphorylation 
Several kinases have been shown to phosphorylate and dephosphorylate 
telomerase, (e.g. PKCα, Akt, Src, PP2A). The model of signaling pathways leading to the 
activation of telomerase begins with mitogenic signals activating PKCα (Li et al. 1998) 
and/or Akt (Kang et al. 1999) while deactivating PP2A (Li et al. 1997). All of which lead 
to a change in the phosphorylation status of telomerase at unknown Serine and/or 
Threonine residues. In contrast, the deactivation of telomerase may begin with DNA 
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damage causing activation of DNA-PK and/or ATM, which activates c-Abl, causing the 
phosphorylation of telomerase at unknown Tyrosine residue(s) (Kharbanda et al. 2000). 
The exact phosphorylation sites on telomerase have not been discovered for any of these 
kinases except for the Src kinase which was shown to phosphorylate hTERT at Y707 to 
induce telomerase exportation by CRM1 after exposure to oxidative stress (Haendeler et 
al. 2003). 
 c-Abl tyrosine kinase has been shown to bind and phosphorylate hTERT but the 
exact phosphorylation site has not been identified. Mouse cells with homozygous 
knockout of c-Abl show an elongation of telomeres suggesting that the phosphorylation 
of mTERT by c-Abl has an inhibitory effect on telomerase activity (Kharbanda et al. 
2000). Human tumor cells show a reduction of in vitro TRAP activity when transiently 
tranfected with c-Abl and an induction of phosphorylation by c-Abl after irradiation. This 
result is similar to that of (Wong et al. 2002) in that irradiation causes the sequestration of 
telomerase to the nucleolus within 1 hour, suggesting that DNA damage causes c-Abl to 
phosphorylate and thus translocate telomerase. In addition, (Kharbanda et al. 2000; 
Etheridge et al. 2002) showed that c-Abl’s SH3 domain bind to a region that has been 
shown by (Kharbanda et al. 2000; Etheridge et al. 2002) to be involved in telomerase 
nucleolar localization. The predicted binding site at amino acids 308-316 is in close 
proximity to Tyrosine 386, which is part of a group of amino acids mutated to show 
nucleolar exclusion. Additionally, this Tyrosine 386 might be on the surface of human 
telomerase based on its relative position on the RNA binding domain of Tetrahymena 
telomerase (Rouda and Skordalakes 2007). It would be interesting to test whether a 
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Y386F mutation could disrupt the phosphorylation of c-Abl and translocation to the 
nucleolus upon irradiation. 
 
Hsp90 chaperone and its inhibition for cancer therapy  
The heat shock protein 90 functions as a dimer in which the C-terminus contains a 
dimerization domain and binding sites for various co-chaperones and the N-terminus 
serves as the ATPase domain and binding site for the co-chaperone, p23. Recent crystal 
and electron micrograph structural data confirms that Hsp90 is a clamp-like dimer bound 
at the C-terminus. Surprisingly, the closed form of Hsp90 does not wrap around its client 
protein, as expected, but provides a bipartite binding surface that forms and dissolves 
with the ATPase cycle (Figure 7) (Ali et al. 2006). ATP binding causes Hsp90’s N-
terminal domains to dimerize, creating positions for binding p23. The p23 co-chaperone 
stabilizes the Hsp90 closed conformation and slows down ATP hydrolysis so that Hsp90-
client protein interactions are extended (Johnson and Toft 1994; Harris et al. 2004; 
Richter and Buchner 2006). 
Although Hsp90 is an abundant protein in the eukaryotic cytoplasm, its role in 
maintaining the conformation and stability of telomerase and key oncogenic client 
proteins such as v-Scr, K-ras, Bcr-Abl, HER2/neu, raf1, and mutated p53 makes it a new 
potential anticancer drug target (Kwon et al. 1992; Zhao et al. 1995; Schulte et al. 1998). 
By simultaneously disrupting multiple pathways critical to cancer cell growth and 
survival, tumors should be more sensitive to the effects of Hsp90 inhibition than are 
normal cells. In addition, it is conceivable that telomeric erosion by Hsp90 inhibition will 
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Figure 7. Hsp90 Chaperone ATPase cycle. The cycle begins with the open 
conformation closing upon ATP binding, which also allows the newly exposed 
hydrophobic residues in the amino, middle, and carboxy domains to bind to the 
client proteins. These slow conformational changes are regulated positively by 
Aha1 and negatively by Sti1 and Cdc37. Co-chapeone p23 then binds to this 
ATP-complexed active form to slow down ATP hydrolysis and thus maintain a 
semi-closed state in which the N-terminus is transiently dimerized. As ATP 
hydrolysis occurs, the dimer changes into a closed state with significant tension 
such that ADP release causes the dimer to spring back to the open conformation. 
Courtesy of Richter and Buchner, 2006.
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cause tumor cells to undergo growth arrest or apoptosis sooner because cancer cells 
continuously divide and have less telomeric reserve than stem cells and normal cells. 
 
Telomerase’s Assembly and Telomere Binding by Chaperones 
Using drug inhibitors, recent studies have revealed a better understanding of how 
Hsp90 and p23 function in the assembly and telomere binding of telomerase. Radicicol 
and geldanamycin inhibits Hsp90 by preventing the binding of ATP for the unique 
structural motif called the Bergerat fold (Dutta and Inouye 2000). Specifically, the Hsp90 
dissociation constant for radicicol, geldanamycin and ATP are 19 nM, 1.2 µM and 
400 µM, respectively (Roe et al. 2004). Hsp90 inhibition of the telomerase:chaperone 
complex has been shown to prevent the assembly (8.4 µM GA), as well as inhibiting the 
formed complex’s activity (53 µM GA) (Keppler et al. 2006). Based on the inability to 
undergo hydrolysis in the ATP cycle, Radicicol or Geldanamycin may cause Hsp90 to 
remain associated in a semi-open or semi-closed state around some hydrophobic region 
of telomerase. Indeed, in vitro data show hTR and hsp90 but not p23 remaining bound to 
hTERT upon hsp90 chaperone inhibition (Holt et al. 1999); (Keppler et al. 2006). 
Additionally, Hsp90 serves to help telomerase bind and extend telomeres (Toogun et al. 
2008). Increasing concentration of yeast Hsp90 homolog results in increasing telomerase 
binding and activity in Hsp90 mutant yeast strains while Radicicol decreases binding. 
Furthermore, an optimal concentration of p23 is needed to help telomerase dissociate and 
bind to the telomeres (Toogun et al. 2007). Interestingly, overexpression of a yeast p23 
homolog caused decreased telomerase binding while yeast deficient in this co-chaperone 
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had increased binding to the telomeres.  
 
Telomere Erosion and Telomerase Degradation with Hsp90 inhibition 
Long-term inhibition of Hsp90 with low levels of Radicicol causes telomeres to 
shorten (Compton et al. 2006). The mechanism did not appear to involve telomerase 
since its activity was only transiently inhibited during the first 2 to 6 days of 0.3 µM 
Radicicol treatment. After 6 days, telomerase activity recovered and even exceeded the 
DMSO vehicle control. This low dose of Radicicol was re-applied every two days and 
did not affect the population doublings during the 2 months treatment period of M12, a 
metastatic prostate cell line derived from P69, a human prostate cell line immortalized 
with the SV40 large T antigen (Bae et al. 1994). The shortening of telomeres during this 
time frame was at least in part due to oxygen free radicals produced from the inhibition of 
the Hsp90-nitric oxide synthase (NOS) complex. Preventing NOS from producing free 
radicals with L-NAME allows for the recovery of the telomeres (Compton et al. 2006).   
The indirect inhibition of telomerase through hsp90 chaperone inhibition has also 
been shown to cause the degradation of hTERT. Geldanamycin causes telomerase’s 
degradation, which can be prevented with the proteasome inhibitor, MG132, but not with 
the lysosome inhibitor, E64 (Kim et al. 2005). Prior to degradation, telomerase is 
discovered to interact with the ubiquitin E3 ligase called Makorin RING finger 1 
(MKRN1), binds and ubiquinates the C-terminal domain of hTERT (residues 946-1132). 
Overexpression of MKRN1 leads to decreased telomerase activity and telomere length, 
yet they did not show that Hsp90 inhibition directly leads to ubiquination by MKRN1 and 
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entertain the possibility that another ubiquitin ligase called CHIP may be involved. 
 
Ubiquination and Degradation 
Proteins inside the cell are marked for proteasomal degradation by being 
ubiquinated. The ubiquination cycle consists of E1 activating, E2 conjugating and E3 
targeting enzymes that adds an 8-9 kD moiety onto the lysine of the targeted protein 
(Nandi et al. 2006). In contrast to the E1 and E2 enzymes, many different proteins have 
E3 activity for targeting different substrate proteins. The E3 enzymes can be classified 
into two main categories, HECT (Homologous to E6-AP C-Terminus) and RING (Really 
Interesting New Gene) domain (Jackson et al. 2000). For example, an E3 enzyme with a 
RING-like domain called CHIP can interact with the tetratricopeptide repeats of Hsp70 
and Hsp90 chaperones to ubiquinate many of its client protein (Ballinger et al. 1999; 
Connell et al. 2001). CHIP may function to switch the fate of a protein from folding-
refolding to degradation. Even though ubiquination is mainly associated with 
degradation, various forms of this modification are involved in other cellular functions 
(Nandi et al. 2006). Polyubiquitin chains of specific linkages have been demonstrated to 
be the signal for degradation. However, there is no known recognition sequence of the 
target protein that marks it for degradation. It is speculated that aged proteins with locally 
denatured regions or post-translationally modified proteins (e.g. phosphorylation or 
oxidation) may be selectively degraded.  
Degradation by the 26S proteasome, which consists of two 19S complexes 
flanking a core 20S proteasome, involves de-ubiquination, unfolding, and digestion. 
 25
These functions are carried out by various base and lid subunits of the 19S complex and α 
and β subunits of the 20S complex. Beyond basic house keeping duties, degradation plays 
a role in cell cycle regulation, inflammatory response, immune reponse and 
tumorigenesis, to name a few (Nandi et al. 2006).  The 26S proteasome has been shown 
to exist in the nucleus and cytoplasm (Tanaka et al. 1989; Wojcik and DeMartino 2003). 
Nuclear proteasomes may function to give the cell a tighter regulation of gene expression, 
DNA repair, stress response, and nuclear protein aggregation (von Mikecz 2006). These 
functions are represented in its various substrates: estrogen receptor, Jun, Fos, Myc, p53, 
STAT1, DNA topoisomerase, and CREB-binding protein. 
 
Catalysis by Three Aspartates and Two Divalent Metal Ions 
 The molecular mechanism of the reverse transcriptase of telomerase is based on 
the studies of the reverse transcriptase of HIV-1 and other polymerases that have solved 
crystal structures. Sequence alignment of reverse transcriptase domains from several 
species shows conservation of certain critical amino acids (Nakamura et al. 1997). Three 
Aspartates residing in Motifs 3 and 5 are absolutely conserved and come together in the 
crystal structure of the HIV-1 reverse transcriptase (Figure 8 and 9A). As a whole, this 
structure is often described as a right hand with substructures looking like a palm, thumb, 
and fingers, allowing a “grip” on the DNA. These homologous carboxylate amino acids 
and hand motifs have been identified in sequences of all known RNA-dependent and 
DNA-dependent polymerases (Argos 1988; Delarue et al. 1990). Crystal structure 
analyses of these polymerases have revealed a common feature: two metal divalent ions  
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Figure 8.  Catalytic aspartates’ linear positions and sumoylation potential. Only 
DNhTERT(D712A) disrupts the potential sumoylation consensus sequence 
(ΦKXD/E) where Φ (phi) is a hydrophobic amino acid, K the modified lysine, X any 
amino acid and D/E an aspartate or glutamate. One of the known functions of 
sumoylation is to regulate the nuclear retention of its target protein. In contrast, 
DNhTERT (D712A, D868A, D869A) could be exported due to misfolding caused by 
the mutation.
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Figure 9. Model of the reverse transcriptase domain and coordination of two 
divalent metal ions. A. Three critical Aspartate residues from different regions 
converge to form part of the catalytic cleft of HIV-1 reverse transcriptase (RT) 
(Kohlstaedt et al, 1992). Based on alignment of the RT motifs of various telomerases
with that of HIV-1, this crystal structure can serve as a model for the reverse 
transcriptase motif of hTERT. Figure was created with the program called Protein 
Explorer. B. Model of three Aspartate residues coordinating two divalent metal cations
to aid in the catalysis of the phosphoryl transfer from dNTP to the telomere 3’ terminal 
overhang. Mutation in these aspartates may result in the dominant-negative effect, 
which may be due to the loss of a metal cation. Because binding to a metal cation has 
been shown to induce structural changes in various proteins, this loss could lead to a 
conformational change in telomerase structure. Adapted from Beese and Steitz , 1991.
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such as Mg2+ or Mn2+ being coordinated by the carboxylate side chains. The two metal 
ions support the hydrolytic phosphoryl transfer reaction from the incoming dNTP onto 
the single stranded DNA (Figure 9B) (Beese and Steitz 1991). Specifically, the positive 
charges would stabilize the diphosphate leaving group and facilitate the nucleophilic 
attack of the alpha phosphate by the 3’ OH of the deoxyribose (Huang et al. 1998). If any 
of these three Aspartate residues are substituted, then the metal ion will not be 
coordinated and catalytic activity is eliminated.  
Furthermore, the metal ions may be indirectly involved in conformational changes 
of the reverse transcripase domain. Upon analysis of the superimposed image of the 
unbound and bound reverse transcriptase domains, one can see that DNA binding causes 
the finger and thumb domains to be further apart thus widening the catalytic cleft to 
accommodate the nucleic acid (Rodgers et al. 1995; Huang et al. 1998). Although an 
Aspartate mutant without the metal cofactor may still bind DNA, the inactivity may cause 
the reverse transcriptase domain to spend most of its time in the unbound closed 
conformation. For other proteins’ crystal structure, it has been easier to show that binding 
to a metal ion, or the lack thereof, directly leads to structural changes (Barondeau and 
Getzoff 2004).  
 
Dominant-Negative Telomerase   
In addition to inactivating itself, a dominant negative effect is observed with the 
catalytic site aspartate mutants of telomerase. Characterized by decreased telomerase 
activity or telomere length, DNhTERT expression eventually results in senescence by β-
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galactosidase staining and/or apoptosis by TUNEL staining of various cancer cell lines 
(Hahn et al. 1999; Zhang et al. 1999). Furthermore, Preto et al showed that DNhTERT 
expression in a wild-type p53 background caused senescence, while the additional 
inhibition of p53 by E6 allowed for continued growth until crisis, resulting in apoptosis 
(Preto et al. 2004).  
Most reports of the dominant-negative effect have been derived from the D712A 
V713I mutant initially created in the Weinberg lab (Hahn et al. 1999). Others have 
extended the dominant-negative effect beyond telomere shortening. (Bechter et al. 2004) 
used the D712A V713I mutant to inhibit telomerase in colon carcinoma cells defective in 
mismatch repair in order to observe the emergence of the resistant ALT mechanism. 
Initially, telomeres shorten then recovered after 1st crisis but continued shortening led to a 
2nd crisis in which surviving cells had a wide distribution of telomeres. They suggested 
that the lack of inhibition to homologous recombination due to the MSH6 defect allowed 
for conversion to ALT. (Masutomi et al. 2003) showed that the D712A V713I mutant 
caused senescence and a suppression of proliferation in normal human fibroblast. In 
support of this, they showed shortening of the 3’ single-stranded telomeric overhang 
despite no change in the rate of overall telomere shortening. Surprisingly, they also 
showed the presence of endogenous telomerase in normal human fibroblasts, previously 
thought to lack hTERT expression. They proposed that telomerase functions to maintain 
the 3’ telomeric overhang during the replicative lifespan of human cells. 
By comparing the different aspartate mutants, the dominant-negative effect may 
occur only with the D712A and D868A D869A mutants. Zhang et al created Aspartate 
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mutants of 4 types (D712A, D868A, D868A D869A, D869A) and showed shortened 
telomeres with the D712A mutant (Zhang et al. 1999). Using the D712A V713I and 
D868A D869A mutants, (Roth et al. 2003; Roth et al. 2003) showed decreased telomeres 
and growth with increasing numbers of chromosomal abnormalities. (Sachsinger et al. 
2001) used mouse TERT with the D861A D862A mutation (equivalent to hTERT D868A 
D869A in terms of sequence alignment) to observe a transient decrease in telomerase 
activity and telomere length. (Ouellette et al. 1999) created a D869A hTERT mutant that 
lacked telomerase activity but had no effect on telomere length in normal human 
fibroblast. In contrast to Masutomi et al. (2003), Ouellette et al. (1999) did not observe 
early senescence with the D869A mutant. However, this same D869A mutant decreases 
the frequency of spontaneous immortalization of Li-Fraumeni syndrome-derived breast 
epithelial cells (Herbert et al. 2001). Resistant cells lost expression of this mutant hTERT 
protein and somehow reactivated endogenous telomerase. Taken together, these data 
suggest that the dominant-negative effects have cell-type and investigator-specific 
variability. 
 
Dominant Negative Mechanism 
The mechanism of the dominant-negative effect or how exogenous inactive 
mutants affect the wild-type function is still being debated. Over-expressed inactive 
mutants may bind most of the components needed to form the ribonucleoprotein such as 
hTR and less likely, the abundant chaperones. It is also possible that the inactive 
telomerase may outnumber the wild-type for binding to the telomere. Dominant-negative 
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effects tend to occur with proteins that need to assemble into multimers to be active 
inside cells. Like other reverse transcriptases, dimerization of the wild-type and mutant 
telomerase may create a non-functional dimer. However, two groups have shown that 
dimerization of DNhTERT with wild-type rescued the in vitro telomerase activity 
(Beattie et al. 2001; Moriarty et al. 2002). Therefore, only DNhTERT expression in cells 
causes decreased telomerase activity and telomere erosion. 
In addition to the above theories, we propose 2 new hypotheses that could explain 
the effect of the dominant negative telomerase mutant. First, the Aspartate mutant(s) of 
the catalytic site may cause a conformational change that triggers its recognition as a 
misfolded protein that needs to be degraded. Similar consequences of misfolding and 
degradation are observed for genetic diseases with inactivating mutation (Bross et al. 
1999; Gregersen et al. 2000). Additionally, the inactive heterodimer (DN-
hTERT/w.t.hTERT) may be exported out of the nucleus for degradation. 
Another possible explanation is that the D712A mutation disrupts a sumoylation 
consensus sequence that normally allows the SUMO moiety to retain its substrate protein 
in the nucleus (Figures 8 & 10) (Hay 2001; Wilson and Rangasamy 2001; Wilson 2004). 
Telomerase may then be degraded because it is outside of its normal cellular 
compartment (Goldberg 2003). This alternate hypothesis is based on our computer 
sequence analysis showing a 94% chance that the D712A mutation within the telomerase 
peptide sequence of VKVD potentially disrupts a sumoylation consensus sequence. This 
sequence is ΦKXD/E where Φ is a hydrophobic amino acid, K the modified lysine, X  
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Figure 10. Model of the sumoylation process. Sumoylation is a post-
translational modification whereby a ~11kD SUMO1, 2, or 3 protein is 
conjugated onto the consensus lysine of the target protein (Wilson et al, 2001). 
The cycle of sumoylation is similar to ubiquination, which involves E1 activating, 
E2 conjugating and E3 targeting enzymes. Unlike ubiquination, which mostly 
targets proteins for degradation, SUMO or Small Ubiquitin-like Modifier, is a 
new class of protein involved in various cellular functions such as nuclear 
retention, transcriptional regulation, signal transduction, chromosome 
segregation, cell cycle control, and viral infection response (Hay et al, 2001; 
Wilson et al, 2004). Courtesy of Wilson and Rangasamy, 2001. 
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any amino acid and D/E an aspartate or glutamate. Sequence analysis of other organisms’ 
telomerase revealed that this potential sumoylation site is conserved in mice, xenopus and 
S.cerevisiae. 
To date, sumoylation has been shown for four telomere-binding proteins: TRF1, 
TRF2, TIN2 and RAP1 of the shelterin complex (Potts and Yu 2007). Sumoylation by 
MMS21 SUMO ligase, which is part of the SMC5/6 complex, causes the recruitment of 
these proteins in ALT tumor cells to PML (promyelocytic leukemia) bodies or ALT-
associated PML bodies (APBs). Inhibition of MMS21 prevents APB formation and 
telomere homologous recombination thereby causing telomere shortening and 
senescence.  
 
Study Rationale 
As described above, the telomerase ribonucleoprotein (RNP) is regulated on many 
levels such as transcription, post-translation, assembly, and degradation. For our 
purposes, it is important to understand the mechanism of telomerase degradation, which 
may help to develop more targeted therapies for cancer. Previous studies have shown that 
chaperones function to stabilize the RNPs and that their inhibition results in ubiquitin-
mediated degradation. However, the regulation of telomerase degradation is still not well 
defined. Preliminary evidence suggests that Hsp90 inhibition of nucleoplasmic 
telomerase results in degradation by a nuclear ubiquitin/proteasome pathway such that 
exportation to the cytoplasm is not absolutely required. In contrast, additional preliminary 
data shows an inactive mutated telomerase being slowly exported from the nucleus to the 
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cytoplasm. This nuclear exportation might be due to disruption of a sumoylation 
consensus sequence, which normally allows the SUMO moiety to retain its modified 
substrate in the nucleus and may lead to degradation due to improper localization. 
Alternatively, this mutation of a critical Aspartate residue may be recognized as a 
misfolded protein that needs to be exported to the cytoplasm for refolding or degradation. 
Overall, we propose alternate pathways of telomerase degradation that depend on 
chaperone activity and level of protein damage (Figure 11) (Wickner et al. 1999; Wegele 
et al. 2006). We hypothesize that immediate nuclear degradation occurs if Hsp90 is 
inactive and non-dissociating, causing telomerase to be sensed as a permanently damaged 
protein. In contrast, attempts at refolding an inactive mutated telomerase with other 
chaperones may be initiated upon exportation to the cytoplasm, and if refolding is not 
possible, degradation may occur in the cytoplasm. Thus, our overall goal is to determine 
the mechanism regulating the degradation of telomerase in the nucleus and cytoplasm. 
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Figure 11. Triage model of telomerase refolding and degradation. Like all 
other proteins, the cell must decide the fate of unfolded or misfolded telomerase 
(Wickner et al, 1999). If it is viewed as permanently damaged like that of an 
inactive, non-dissociating Hsp90 then it is immediately ubiquinated and 
degraded in the nucleus. If it is local denatured or misfolded, then it is exported 
to the cytoplasm where it is transferred to other chaperones for refolding back 
into native protein. If refolding is not possible then it is degraded by the 
cytoplasmic ubiquination proteasome pathway. Aggregates are formed if 
degradation can’t occur. Adapted from Wegele et al, 2006 and Wickner et al, 
1999. 
 36
 
Chapter 2 
Materials and Methods 
 
Cell culture and Chemicals 
 293 and 293T cell lines were grown in DMEM with 10% CCS (cosmic calf 
serum) and gentamicin (30 µg/mL). P69 cells were grown in RPMI with 5% FBS 
supplemented with ITS (insulin, transferrin, selenium), dexamethasone, and gentamicin. 
All derived cell lines with wild-type and mutant GFPhTERT were maintained in the same 
growth media as the parental cell lines. Selection occurred with 700 ng/mL of puromycin 
or 140 µg/mL of hygromycin. After confirmation of stable expression of the nuclear 
fluorescence for more than 2 weeks, derived cell lines were taken off the selection 
antibiotic. All cell lines were incubated at 37oC with 5% CO2. Cells were treated where 
indicated with the following drugs: Radicicol, MG132 and DMSO from Sigma-Aldrich 
and Leptomycin B from LC Lab Inc. 
 
Plasmid construction 
 The following plasmids were gifts from the indicated investigators: pBabe hygro 
GFPhTERT from Dr. Kathleen Collins, pBabe-puro DNhTERT (D712A V713I) from Dr. 
William Hahn, pCR hTERT-HA nes from Dr. Hiroyuki Seimiya. pBabe-puro 
GFPhTERT was created by cutting pBabe-hygro GFPhTERT with EcoR1 and Sal1, then 
ligating the GFPhTERT fragment to the linearized EcoR1/ Sal1 pBabe-puro. pBabe-puro 
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GFPDNhTERT was created by cutting pBabe puro DNhTERT with Mlu1 and Sal1 then 
ligating the DNhTERT fragment to the linearized Mlu/Sal1 pBabe puro GFPhTERT 
fragment. pBabe-puro GFPhTERT nes were created by cutting pCR hTERT-HA nes with 
Sbf1 and Bsm1 then ligating the fragment to the linearized Sbf1/Bsm1 pBabe puro 
GFPhTERT fragment. The double mutant pBabe-puro GFPDNhTERT nes was created 
by cutting pCR hTERT-HA nes with Sbf1 and Bsm1, then ligating the hTERT nes 
fragment to the linearized Sbf1/Bsm1 pBabe-puro DNhTERT D712A fragment. pBabe 
GFP hygro and pBabe GFP puro were created by inserting a BamH1/Xho1 fragment of 
GFP obtained from pHR CMV GFP ires puro (supplied by  Dr. John C. Kappes) into 
linearized BamH1/Sal1 pBabe hygro and pBabe puro, respectively. pHR CMV 
GFPhTERT ires puro, pHR CMV GFPDNhTERT ires puro, pHR CMV hTERT ires puro 
and pHR CMV DNhTERT ires puro were created by subcloning GFPhTERT, 
GFPDNhTERT, hTERT and DNhTERT as EcoR1/Sal1 fragments into pEGFP-N1. From 
there, these fragments were ligated as BglII/Sal1 fragments into linearized BamH1/Xho1 
pHR CMV ires puro, originally supplied by as pHR CMV GFP ires puro.  
  
Virus production and infection 
 Retroviruses were produced by co-transfection of pCL ampho, pME VSVg and 
the pBabe plasmid of interest into the 293T cell line using Fugene 6. Lentiviruses were 
produced by co-transfection of pPAX, pMD2G, and the lentiviral plasmid of interest into 
the 293T cell line using Fugene 6. Co-transfection of 5 µg of total DNA with 20 µl of 
Fugene 6 was applied onto 293T cells at 25% confluency on a 10 mm plate. Viruses were 
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produced over 7 days, and the viral supernatants were harvested, pooled, and filtered 
through a 0.45-micron filter. Viruses were either used immediately or stored at 4oC for up 
to 1 week, or immediately aliquoted and stored in -80oC. Viral media was combined with 
the target cells’ media in a 1:1 or 1:2 ratio and allowed to incubate at 37oC with 5% CO2 
with target cells for 2 days before selection began with the appropriate antibiotics, 
puromycin or hygromycin. 
 
TALA- Telomere Amount and Length Assay 
 Cells were grown on a 10 cm2 tissue culture plate until nearly confluent, then 
washed with PBS. 3 mL of lysis buffer (10 mM Tris HCl pH 8.5, 5 mM EDTA, 0.2% 
SDS, 0.2 M NaCl) with 100 µg/mL of proteinase K was applied to the plate. The lysates 
were  transferred to a 15 mL conical tube and incubated at 55oC with agitation for 1 hour. 
Afterwards, an equal volume of isopropanol was added to precipitate the DNA. The DNA 
was spooled out, washed with 70% ethanol and dissolved in DNase-free water at 55oC for 
1 hour or at 37oC overnight. 15 ug of DNA was cut with Hinf1, HaeIII and Hha1 in 
ReACT 2 buffer (Invitrogen) for 6 hours at 37oC. γ-32P radio-labeled telomeric probe was 
mixed with 5 µg of digested DNA, then incubated at 95 oC for 3 min and then hybridized 
at 55oC overnight. 2.5 µg of DNA hybridized to the radio-labeled telomeric probe was 
loaded onto a 0.7% agarose gel then electrophoresed at 210 V for 4.5 hours. The gel was 
dried at room temperature and exposed to a phosphorimaging screen overnight. The 
image was obtained with a phosphorimager (Molecular Dynamics) and analyzed with 
ImageQuant. 
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TRAP- Telomerase Repeat Amplication Protocol (telomerase activity assay) 
 Using the TRAPEZE kit, the TRAP assay was performed according to protocol 
from the TRAPEZE kit (Chemicon). Cells were lysed in a buffer containing 10 mM Tris-
HCl pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM Benzamidine, 5 mM β-
mercaptoethanol, 0.5% CHAPS, 10% glycerol. 200 ng/µl of protein or 1000 cells were 
used in each sample. Lysates were incubated with a γ-32P radio-labeled oligonucleotide 
telomeric mimic at room temperature for 30 minutes. 2-step PCR was performed with 
94oC/30 s, 60oC/30 s for 27 cycles in a thermocycler. Samples were loaded onto a 10% 
polyacrylamide gel and electrophoresed at 210V for 3.5 hours. The gel was exposed to a 
phosphor-screen overnight, then scanned and visualized with a Phosphorimager.  
  
Western analysis 
 Cells were washed in PBS then lysed with modified RIPA buffer (50 mM Tris-
HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1X 
protease inhibitor cocktail (Calbiochem 539137)). After removing the cellular debris by 
spinning at 12000XG for 10 min at 4oC, lysates were sonicated for 1 min, then quantified 
using the BioRad DC protein assay kit and a spectrophotometer. The lysates were mixed 
with 4X Laemmli sample buffer and denatured for 15 minutes at 80oC. 50 µg of protein 
were loaded on each lane on a 4% stacking, 10% separating SDS-PAGE gel, and run at 
100V for 1.5 h. The proteins in the gel were transferred to a nitrocellulose membrane at 
100V for 1.5 h. The blot was blocked for 1 h in Tween-buffered saline with 5% non-fat 
dried milk. Primary antibodies were then added to the blocking buffer and incubated at 
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room temperature for 1 hour with rocking. The primary antibodies to the following 
proteins were used: hTERT at 1:1000 dilution (Rockland), β-actin at 1:5000 dilution 
(Sigma), GFP and Ubiquitin at 1:1000 dilution (Santa Cruz). The blot was washed in 1X 
PBS/0.1% Tween three times for 15 min each. Secondary antibodies conjugated to 
horseradish peroxidase (BioRad) were added to the blocking buffer. The blot was 
incubated at room temperature for 1 hour with rocking, and then washed three times for 
15 min each with 1X PBS/1% Tween. Protein-antibody complexes were detected with 
the Supersignal West Pico Chemiluminescent kit and exposed to autoradiographic film 
for varying lengths of time (2 seconds to 7 minutes).   
 
Immunoprecipitation 
 Equal numbers of cells were plated in order to obtain confluent cells on the day 
experiments were conducted. Confluent cells on a 102 cm tissue culture plate were 
washed and lysed directly in the plate with 1 mL of modified RIPA on ice. Lysates were 
centrifuged at 12000 X G for 10 min at 4 oC. To the 1 mL of supernatant, 4 µg of a 
polyclonal rabbit anti-GFP antibody (Santa Cruz sc-8334) was added and mixed 
overnight at 4 oC. 50 µL of a washed 50/50 slurry of Protein A agarose beads (Roche) 
was then added and mixed for several hours or overnight at 4oC. Beads were spun down 
at 6000 X G for 2 min, and then washed three times with 500 µL of modified RIPA. 75 
µL of modified RIPA and 25 µL of 4X Laemmli sample buffer were then added to the 
beads. The slurry was heated to 80oC for 15 min. The supernatant was transferred to a 
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600 µL eppendorf tube and the samples were either used in the Western analysis 
immediately or stored at –20 oC. 
 
Semi-quantitative RT-PCR 
 Total RNA was obtained from equal number of cells according to the protocol 
from the RNeasy kit (Qiagen). RNA levels were measured on the spectrophotometer. 
Equal amount of RNA was immediately reverse transcribed using the protocol from the 
Retroscript kit (Ambion) with random primers. Semi-quantitative PCR was performed 
according to the protocol of the QuantumRNA 18S Internal Standards (Ambion). All 
samples were amplified with the following parameters: an 18S primer : Competimer ratio 
of 1:9 and PCR cycles of initial 5 min at 95oC, and then 22 cycles of 45 sec at 95oC, 30 
sec at 62oC, 45 sec at 72oC.  Endogenous hTERT cDNA was amplified with the 
following sequence: 5’ GAC TCG ACA CCG TGT CAC CTAC 3’ and 5’ ACT CAG 
CCT TCA GCC GGA CAT 3’. The exogenous hTERT from the pBabe-based vectors 
was amplified with the following sequence: 5’ GAC TCG ACA CCG TGT CAC CTAC 
3’and 5’ GAC ACA CAT TCC ACA GGT CG 3’. The exogenous hTERT from the pHR-
based vectors was amplified with the following sequence: 5’ GAC TCG ACA CCG TGT 
CAC CTAC 3’ and 5’ GAC CTT GCA TTC CTT TGG CG 3’. PCR products were 
separated on a 2% agarose gel and visualized with ethidium bromide. 
 
Fluorescence microscopy 
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 For epi-fluorescence microscopy, cells were grown on tissue culture plates in 
complete growth media without phenol red to reduce the background fluorescence. To 
visualize DNA in living cells, Hoescht 33342 was added to the media for 30 min and then 
washed with PBS before visualization. Images were captured on an Olympus IX70 
Inverted Fluorescent microscope.   
For confocal fluorescence microscopy, cells were grown on chambered coverglass 
or slides in complete growth media without phenol red. In addition, 293 cells must be 
grown on 1% gelatin in order to adhere to the glass. P69 cells were washed with PBS 
then fixed with 3.7% formaldehyde for 10 min. For 293 cells, 40% paraformaldehyde at 
pH 7.4 must be applied directly onto cells growing in complete media without prior PBS 
wash. Add appropriate volume so that final concentration is 4% paraformaldehyde. All 
cells were permeabilized with 0.5% Triton X-100 for 10 min then washed with PBS.  
Cells were blocked with 4% BSA in PBS for 1 hour then incubated with 4% BSA in PBS 
with a polyclonal antibody at 1:100 dilution generated against a 20S proteasome subunit 
(BIOMOL PW8155) or nucleolar’ fibrillarin (Santa Cruz H-140 sc-25397) overnight at 
4oC. After washing with PBS, cells were incubated with 4% BSA in PBS with a highly 
crossed absorbed Alexa Fluor 647 goat anti-rabbit IgG (Invitrogen A21245) for 2 hours 
at room temperature. Cells were stained with 4’,6-diamidino-2-phenylindole (DAPI) 
during mounting in Vectashield (Vector Lab H-1000). A Leica TCS-SP2 AOBS confocal 
laser scanning microscope with a spectrophotometer scan head to tune the detectors to the 
appropriate emission wavelength was used. Image analyses were performed with Leica 
Confocal Software, ImageJ and IPLab. Statistics were performed with the paired t test.  
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Chapter 3 
 
Nuclear Degradation of Telomerase upon Hsp90 Inhibition 
 
 
Creation and characterization of P69 GFPhTERT cell line 
 The pBabe hygro GFPhTERT plasmid, encoding a full length hTERT fused to a 
N-terminal GFP tag, produced a fully functional active telomerase (Wong et al. 2002). 
pBabe hgyro GFPhTERT or pBabe hygro or pBabe hygro GFP was co-transfected with 
pCL ampho, the packaging plasmid, and pME VSVg, the envelope plasmid, into the viral 
packaging cell line, 293T. Retroviruses were used to infect P69, a prostate cell line 
created by SV40 large T antigen immortalization of prostate epithelial cells from a 
patient with benign prostate hyperplasia (Bae et al. 1994). After selection for 2 weeks 
with 150 µg/ml of hygromycin, a mass population of P69 GFPhTERT hygro cells was 
created. Other precancerous and cancerous cell lines, e.g. SW39 and DU145 were also 
infected, but preliminary tests showed P69 GFPhTERT had the highest fluorescence 
among them. To confirm the expression of active GFPhTERT, the cells were analyzed 
for fluorescence pattern, protein molecular weight, and telomere length. Western analysis 
using the hTERT antibody from Rockland showed the proper molecular weight of 
approximately 153 kD, a combination of 127 kD for hTERT and 26 kD for GFP (Figure 
12A). P69 parental cells have undetectable levels of endogenous hTERT protein, 
although its telomerase activity has been shown (Akalin et al. 2001). MCF-7, a breast 
carcinoma cell line, served as a positive control and an indicator of the molecular weight 
of endogenous hTERT. BJ, a foreskin fibroblast primary cell line, served as the negative 
control for hTERT expression. The mean telomere length increased from approximately  
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Figure 12. GFPhTERT is present at the proper molecular weight and active.
A. Western analysis using the hTERT antibody from Rockland shows the proper 
molecular weight of approximately 153 kD for P69 GFPhTERT, a combination of 
127 kD for hTERT and 26 kD for GFP. Endogenous level of hTERT in P69 is 
undetectable by Western blot. BJ, a primary fibroblast cell line, and MCF-7, a 
breast carcinoma cell line, served as negative and positive control, respectively.  
B. The mean telomere length is increased from ~2.8 kb in P69 parental (Lane 1) 
and P69 pBabe (Lane 2) to 5.7 kb in P69 GFPhTERT (Lane 3).
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2.8 kb in P69 parental to 5.7 kb in P69 GFPhTERT cells (Figure. 12B). The fluorescence 
pattern was similar to that described by Wong et al, (2002) in that the GFPhTERT is 
mostly nucleoplasmic in cancerous cells and cells immortalized with SV40 large T 
antigen (Figure 13A). This combination of data confirmed that the exogenous 
GFPhTERT is present and functionally active in the P69 GFPhTERT cell line, which was 
subsequently used to study the effects of various drug treatments on telomerase.  
 
Hsp90 inhibition decreases fluorescence of GFPhTERT in a time and dose 
dependent manner  
 It has been shown by Kim et al. (2005) that Hsp90 inhibition by Geldanamycin 
causes telomerase degradation in a time and dosage dependant manner using Western 
analysis. By using the P69 GFPhTERT cell line, we wanted to develop an efficient 
method to determine in real-time the location and protein expression of telomerase in 
living cells after Hsp90 inhibition. We decided to use Radicicol because preliminary data 
showed it to be an efficient Hsp90 antagonist with less cellular toxicity than 
geldanamycin. The decrease in fluorescence intensity upon Radicicol treatment was 
found to be time-dependent as measured by confocal laser microscopy. During the 2 
hours time lapse, the fluorescence was gradually decreased to 31.7% in Radicicol-treated 
cells as compared to 82.4% in DMSO-treated control cells (Figures 13 and 14). 
Additionally, Radicicol decreases the fluorescence precipitously from 0 µM to 0.1 µM 
then gradually in a dose-dependent manner from 0.1 µM to 3 µM (Figure 15).    
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Figure 13. Hsp90 inhibition causes a time-dependent decrease in 
fluorescence. A. P69 GFPhTERT treated with DMSO maintains the same 
fluorescence intensity during the 2+ hour time lapse. B. P69 GFPhTERT treated 
with RAD (0.5 µM) shows diminishing fluorescence with time. Scale bar equals 
47.62 µm. 
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Time Lapse Fluorescence of P69 GFPhTERT during Treatment
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Figure 14. P69 GFPhTERT diminishing fluorescence with Hsp90 inhibition 
is time-dependent. Radicicol (0.5 µM) treatment (■) causes a gradual reduction 
in the fluorescence intensity such that after 2 hours, it is at 36.7% as compared to 
the DMSO control treatment (♦) of  83.4%. Even though confocal laser scanning 
of samples occurred 20 minutes apart, there is still some photobleaching of 
fluorescence as seen by the common 10% reduction after 20 minutes. Experiments 
were repeated 3 times. 
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Figure 15. Dosage response of P69 GFPhTERT during 2 hours of Radicicol 
treatment. Fluorescence intensity decreases precipitously from 0 µM (100 %) to 0.1 
µM (39 %) then gradually from 0.5 µM (37 %) to 3 µM (22 %). Different concentrations 
of Radicicol was applied 20 minutes apart giving enough time to measure fluorescence 
using the confocal laser scanning microscope. Three fields of view of approximately 
equal cellular density were taken for each concentration. Drug conc. increases from top 
left to right then bottom left to right. Bottom far right picture is P69 pBabe control. 
Scale bar is 75 µM.
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The time and dose dependent responses of P69 GFPhTERT suggest that live cell imaging 
analysis of the fluorescence intensity is an effective method to visually determine the fate 
of GFPhTERT after Hsp90 inhibition. 
  
Inhibition of degradation by the proteasome inhibitor MG132, but not by the 
nuclear exportation inhibitor Leptomycin B 
 Kim et al. (2005) have shown that telomerase is degraded by the proteasome, not 
by lysosomes, upon Hsp90 inhibition. Because proteasomes are localized throughout the 
cell’s nucleoplasm and cytoplasm, we wanted to extend this analysis by determining if 
the nuclear-localized telomerase is degraded in the nucleus or is exported and then 
degraded in the cytoplasm. After treating P69 GFPhTERT cells with 0.5 µM Radicicol 
for 6 hours, the fluorescence decreased to 28% of the DMSO control, and a similar 
decrease was seen by immunoblot analysis (Figures 16 and 17).  Concurrent treatment of 
these cells with Radicicol (0.5 µM) and the proteasome inhibitor, MG132 (10 µM), for 6 
hours completely prevented the degradation of telomerase induced by Hsp90 inhibition, 
as shown both by the Western analysis and fluorescence measurements, when compared 
to control. This combination treatment also caused the aggregation of the GFPhTERT 
within the nucleus starting at 4 hours and continuing to 6 hours (Figure 16). In addition, 
the proteasome inhibitor alone showed the ability to prevent the regular turnover of 
GFPhTERT on the immunoblot and confocal analysis, causing an increase to 129% of 
control. Once again, aggregation of GFPhTERT started to appear at 4 hours and   
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DMSO Radicicol + MG132Radicicol
LMBRadicicol + LMBMG132
Figure 16. P69 GFPhTERT show different changes in fluorescence intensity 
and pattern after various treatments. Cells were treated to 6 hours of 0.5 µM
Radicicol, 10 µM MG132, 100 nM LMB and their combinations. Hsp90 
inhibition caused a reduction in intensity. The combination of proteasome and 
Hsp90 inhibition caused the intensity to remain the same as control but 
aggregates are formed. Proteasome inhibition alone causes aggregation as well 
but with higher intensity. The combination of Hsp90 and nuclear exportation 
inhibition still caused a reduction in fluorescence intensity. Leptomycin B alone 
caused a slight reduction in intensity but no change in pattern.
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Figure 17. Correlation between fluorescence intensity and protein levels in 
P69 GFPhTERT after various treatments. Cells were treated to 6 hours of 0.5 
µM Radicicol, 10 µM MG132, 100 nM LMB and their combinations. For each 
sample, three fields of view of approximately equal cellular density were mearsured for 
fluorescence. Rockland anti-hTERT and Sigma anti-actin antibodies were used. 50 µg 
of protein was loaded for each lane.
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continued to 6 hours (Figure 16). Concurrent treatment with Radicicol and the nuclear 
exportation inhibitor, 20 nM leptomycin B, still caused the degradation of telomerase to 
29% of control. Similar results occurred when repeated with a higher concentration of 
leptomycin B at 100 nM (Figure 16 and 17). After 6 hours of treatment with 100 nM of 
the exportation inhibitor alone, there was a relatively small reduction in protein level and 
in fluorescence to 87% of control. To show Radicicol’s specificity towards telomerase: 
chaperone complexes, similar drug treatments were applied to P69 cells expressing GFP 
alone. There was no change in the fluorescence after 4 hours of Radicicol treatment as 
compared to the DMSO control, suggesting that GFP is not affected by Hsp90 inhibition 
(Figure 18). Overall, the changes in fluorescence intensity and protein level in the various 
drug treatments of P69 GFPhTERT concur with one another, suggesting that telomerase 
does not need to be exported for degradation and can be degraded in the nucleus upon 
Hsp90 inhibition. 
An additional issue that needs to be addressed with this set of experiments is 
toxicity. The exportation inhibitor treatment resulting in 87% reduction in fluorescence 
was used to exemplify the toxic effect of Leptomycin B on telomerase such that exposure 
beyond 100 nM or 8 hours causes cell to die. Similarly, treatment with the proteasome 
inhibitor, MG132, at concentration greater than 20 µM or for longer than 8 hours has 
lethal effects. In contrast, cells can tolerate and continue to divide with long term (weeks) 
treatment of Radicicol at 0.5 µM. Therefore, inhibition of proteasome degradation and 
nuclear export but not Hsp90 can cause cellular stress and side effects if treatment occurs 
beyond the parameters mentioned. 
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Figure 18. P69 GFP showed no significant changes in fluorescence intensity 
nor pattern with inhibition of Hsp90, proteasome, nuclear exportation or 
their combinations. P69 GFP cells were treated with 0.5 µM Radicicol, 10 µM
MG132, 100 nM LMB for 4 hours. For each sample, three fields of view of 
approximately equal cellular density were measured for fluorescence. 
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Telomerase activity is reduced in the P69 parental cell line after 24 hours 
To determine the effect of Hsp90 inhibition on telomerase activity, a time-course 
TRAP assay with Radicicol was conducted on the P69 parental cell line. These cells were 
plated and then exposed to a one time treatment with 0.5 µM Radicicol. Cells were lysed 
at various time-points and equal amounts of protein were used in the TRAP assay. 
Phosphorimager analysis shows no significant decrease in activity after 6 hours of 
Radicicol treatment when compared to the 6 hour DMSO control (Figure 19). However, 
by 24 hours the activity decreased to 48% then recovered to 56% at 36 hours, 68% at 2 
days and 115% at 4 days. These changes indicated that Hsp90 inhibition of telomerase 
activity is time-dependent and occurs after 24 hours at the specified concentration. The 
lack of change in activity after 6 hours suggested a disparity with the decrease in protein 
level and fluorescence of GFPhTERT after the same amount of time. Further analysis 
needs to be conducted including a dosage response in TRAP activity after 6 hours of 
treatment.   
 
No change in telomerase activity within 6 hours for various drug treatments 
To determine if there is a correlation between hTERT degradation and activity 
with the various drug treatments, P69 parental and P69 GFPhTERT cell lines were 
exposed for 6 hours to Radicicol, MG132, LMB alone or in combination and then 
subjected to the TRAP assay. The cells were then lysed, and 200 ng of protein from P69 
parental samples and 20 ng of protein from P69 GFPhTERT samples were used in the  
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Figure 19. P69 parental cells showed a reduction in telomerase activity with 
Hsp90 inhibition after 24 hours. Initially, there was no significant decrease in 
activity after 6 hours of 0.5 µM Radicicol. However, after 24 hours there was 
~50 % activity followed by a recovery. 200 ng of protein was loaded for each 
sample. Changes in TRAP activity were compared to the DMSO control of 6 
hours.
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TRAP assay. These samples were repeated in another experiment with 1000 cells for P69 
and 100 cells for P69 GFPhTERT. Radicicol alone caused only a 10% and 5% reduction 
in activity for P69 and P69 GFPhTERT, respectively (Figure 20 and 21). In contrast to 
the prevention of degradation in the protein and fluorescence studies, concurrent 
treatment with the Hsp90 and proteasome inhibitors caused a further decrease in activity 
to 66% for P69 and 82% for P69 GFPhTERT. Similar results occurred with the 
combination of Radicicol and Leptomycin B, which showed a further decrease in activity 
to 65% for P69 and 90% for P69 GFPhTERT. In both cell lines, the proteasome inhibitor 
alone or exportation inhibitor alone caused less reduction in activity than the combination 
but more when compared to the Hsp90 inhibitor alone. This suggested that MG132 at 
10µM and LMB at 100 nM may have a toxic affect on telomerase activity or the assay 
itself. Overall, the lack of a dramatic decrease in activity in these P69 and P69 
GFPhTERT cells upon Hsp90 inhibition does not correlate with the marked decrease in 
protein level and fluorescence of GFPhTERT. This discordance suggests a model in 
which Radicicol causes the degradation of GFPhTERT:chaperone complex without hTR 
but not the GFPhTERT:hTR ribonucleoprotein, which may not be effected by Hsp90 
inhibition in the short-term. This will be explored further in the discussion. 
 
Ubiquination of GFPhTERT for degradation 
 To determine whether telomerase is ubiquinated for degradation, P69 GFPhTERT 
cells were treated with the various drugs then immunoprecipitated with a GFP antibody, 
followed by immunoblotting with an ubiquitin antibody. After 2 hours of drug treatment,  
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Figure 20. P69 parental cells’ changes in telomerase activity does not 
correlate to the reduction of GFPhTERT protein levels in various 
treatments. Cells were treated to 6 hours of 0.5 µM Radicicol, 10 µM MG132, 
100 nM LMB and their combinations. 200 ng of protein and 1000 cells (image 
above) were loaded for each sample in the 1st and 2nd trial, respectively. Both 
trials had similar results.  Changes in TRAP activity were compared to the 
DMSO control of 6 hours.
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Figure 21. P69 GFPhTERT cells’ changes in telomerase activity does not 
correlate to the reduction of GFPhTERT protein levels in various 
treatments. Cells were treated to 6 hours of 0.5 µM Radicicol, 10 µM MG132, 
100 nM LMB and their combinations. 20 ng of protein and 100 cells (image 
above) were loaded for each sample in the 1st and 2nd trial, respectively. Both 
trials had similar results.  Changes in TRAP activity were compared to the 
DMSO control of 6 hours.
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P69 GFPhTERT cells treated with Radicicol alone showed an increase in ubiquination of 
GFPhTERT as compared to the DMSO control (Figure 22). Poly-ubiquinated proteins 
usually appear as high molecular weight smears which is diagnostic for proteins marked 
for proteasomal degradation (Kim et al, 2005). Inhibition of the Radicicol-induced 
degradation with the proteasome inhibitor, MG132, dramatically increased the amount of 
observable ubiquination. This combination showed higher levels than that of the 
proteasome inhibitor alone, further suggesting that Hsp90 inhibition of the telomerase: 
chaperone complex induces the ubiquination of GFPhTERT. The other combination 
treatment of Radicicol and Leptomycin B showed similar levels of ubiquination as the 
Radicicol treatment alone. The exportation inhibitor was not able to prevent the 
ubiquination of GFPhTERT, thus suggesting that the ubiquitin tag can be covalently 
attached in the nucleus. Leptomycin B treatment alone had no effect on the level of 
ubiquination. The lysate from P69 GFPhTERT served as the positive control showing all 
of the various ubiquinated products in the proteome. These data further suggest that 
telomerase is poly-ubiquinated and degraded in the nucleus when treated with an Hsp90 
antagonist, and that prevention of degradation leads to marked increases in the level of 
ubiquinated GFPhTERT. 
 
Co-localization of GFPhTERT & nuclear proteasomes following inhibition of 
degradation and aggregation around nucleoli with distress 
With previous data suggesting that telomerase is degraded in the nucleus, we 
wanted to provide further proof of nuclear degradation of telomerase upon Hsp90  
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Figure 22. GFPhTERT ubiquination with Hsp90 inhibition. P69 GFPhTERT
cells were treated with the various drugs and combinations for 2 hours then 
immunoprecipitated with anti-GFP followed by Western analysis with anti-Ub. 
Drug concentrations include 0.5 µM Radicicol, 10 µM MG132, 20 nM LMB. 
P69 GFPhTERT lysate and P69 GFP immunoprecipitate served as the positive 
and negative control, respectively. The IgG heavy chain served as the loading 
control.
 61
inhibition by performing co-localization studies. P69 GFPhTERT was plated on chamber 
slides and treated for 6 hours with various drugs alone or combination: 5 µl DMSO, 0.5 
µM RAD, 10 µM MG132, 20 nM LMB. In comparison to the nucleolar exclusion pattern 
of the P69 GFPhTERT live cell seen in Figure 16 (DMSO treated), the process of fixation 
caused some GFPhTERT molecules to aggregate near the nucleoli (Figure 23). 
Antibodies to the 20S proteosomal subunit show its distribution throughout the cell 
including the cytoplasm and nucleoplasm. Additionally, antibodies to fibrillarin, which is 
part of the dense cyto-architecture of the nucleoli, illustrated each nucleolus as a cluster 
of punctate bodies. The induction of GFPhTERT degradation by RAD causes the cells to 
lose most of the fluorescence, while the remaining GFPhTERT molecules aggregate to 
the nucleoli and some other unknown structures but not the 20S proteasomes (Figure 24).  
The lack of reduction in telomerase activity (Figure 21) may be due to these remaining 
GFPhTERT assembled with hTR but not inhibited by 6 hours of Radicicol treatment.  
When Radicicol-induced degradation is inhibited with MG132, GFPhTERT co-localizes 
with the nuclear proteasome (yellow in merged panel) but not with nucleoli (Figure 25). 
This combination of inhibition caused the aggregation of GFPhTERT and 20S 
proteasomes molecules, thus allowing the co-localization in the nucleoplasm. In contrast, 
inhibition of degradation with MG132 alone causes GFPhTERT to translocate to the 
nucleoli with little to no aggregation at the nuclear proteasome (Figure 26). Taken 
together, the co-localization studies suggest that GFPhTERT is degraded by the 20S 
proteasome in the nucleoplasm and translocated to the nucleoli after distress. 
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GFPhTERT DMSO merged 20S proteasome
GFPhTERT DMSO merged nucleoli
Figure 23. P69 GFPhTERT does not co-localize with the nuclear 
proteasomes nor nucleoli under normal condition. P69 GFPhTERT cells were 
treated with the solvent control of DMSO for 6 hours. No co-localization 
occurred for the merging of GFPhTERT (green) with proteasomes (top middle) 
nor with nucleoli (bottom middle). Cells were immunostained with the 20S 
antibody (BIOMOL PW8155) in the top panel and with the fibrillarin antibody 
(Santa Cruz sc-25397) in the bottom panel. Anti-rabbit secondary antibody was 
Alexa Fluor 647 (Invitrogen A21245). Scale bar is 14.37 µm.
63
merged 20S proteasomeGFPhTERT Rad
merged nucleoliGFPhTERT Rad
Figure 24. P69 GFPhTERT translocate to some nucleoli after inhibition of 
Hsp90-induced degradation. P69 GFPhTERT cells were treated to 0.5 µM
Radicicol for 6 hours. No co-localization occurred for the merging of the 
GFPhTERT (green) and proteasome (red) nor nucleoli (red). Cells were 
immunostained with the 20S antibody (BIOMOL PW8155) in the top panel and 
with the fibrillarin antibody (Santa Cruz sc-25397) in the bottom panel. Anti-
rabbit secondary antibody was ALexa Fluor 647 (Invitrogen A21245). Scale 
bar is 14.37 µm.
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GFPhTERT Rad & MG132 merged 20S proteasome
GFPhTERT Rad & MG132 merged nucleoli
Figure 25. P69 GFPhTERT co-localize with the nuclear proteasome after 
inhibition of Hsp90-induced degradation. P69 GFPhTERT cells were treated to 
0.5 µM Radicicol and 10 µM MG132 for 6 hours. After staining for the 20S 
proteosome, cells in the merged top panel showed co-localization (yellow) of the 
aggregated GFPhTERT(green) and the nuclear proteasome (red). No co-
localization occurred for the merging of the aggregated GFPhTERT (green) and 
nucleoli (red). Cells were immunostained with the 20S antibody (BIOMOL 
PW8155) in the top panel and with the fibrillarin antibody (Santa Cruz sc-25397) 
in the bottom panel. Anti-rabbit secondary antibody was ALexa Fluor 647 
(Invitrogen A21245). Scale bar is 14.37 µm.
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GFPhTERT MG132 merged proteasome
GFPhTERT MG132 merged nucleoli
Figure 26. P69 GFPhTERT translocate to the nucleolus after inhibition of 
degradation. P69 GFPhTERT cells were treated to 10 µM MG132 for 6 hours. No co-
localization occurred for the merging of the aggregated GFPhTERT (green) and 
proteasome(red). Cells were immunostained with the 20S antibody (BIOMOL PW8155) 
in the top panel and with the fibrillarin antibody (Santa Cruz sc-25397) in the bottom 
panel. Anti-rabbit secondary antibody was ALexa Fluor 647 (Invitrogen A21245). Scale 
bar is 14.37 µm.
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Chapter 4 
Cytoplasmic Degradation and Mechanism of Dominant Negative hTERT 
 
Creation of GFPhTERT mutants retroviral plasmids 
 To test the hypothesis that the dominant-negative mutation (D712A V713I) 
causes the cytoplasmic degradation of the exogenous telomerase catalytic component, 
hTERT, and to determine the effects on the endogenous hTERT, a series of subcloning 
experiments were conducted to place the various mutants into the retroviral vector. 
GFPhTERT was subcloned from a pBabe-hygro vector into a pBabe-puro vector for 
efficiency of selection after retroviral infection. The Mlu1 to Bsm1 restriction fragment 
containing the mutation from pBabe-puro DNhTERT D712A V713I was used to replace 
the corresponding wild-type fragment of pBabe-puro GFPhTERT to create pBabe-puro 
GFP-DNhTERT D712A V713I. The Mlu1 Bsm1 restriction fragment from pCR hTERT 
nes HA was used to replace the corresponding wild-type fragment of pBabe-puro 
GFPhTERT to create pBabe-puro GFPhTERT nes. To create the double mutant of 
pBabe-puro GFP-DNhTERT D712A V713I nes, the Sbf1 Bsm1 restriction fragment from 
pCR hTERT nes HA was used to replace the corresponding fragment from pBabe-puro 
GFP-DNhTERT D712A V713I. Both vectors containing the nuclear export signal 
mutation lack the hemagglutinin tag at the C-terminus that came with the original vector 
from Seimiya et al (2000). It was deleted because the HA tag has been shown to abolish 
the in vivo activity of telomerase (Counter et al. 1998). Restriction analysis and DNA 
sequencing was used to verify each construct (Figure 27).  
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WT F      V     K       V       D       V       T      G       A
D712A 
V713 I
F        V     K       V       A I T       G       A
WT R      R      K      L      F      G      V       L      R     L K      C     H
nes R      R      K     A F     G       V      A R     A K      C     H
Figure 27. pBabe-puro GFPhTERT, pBabe-puro GFPDNhTERT (D712A 
V713I), pBabe-puro GFPDNhTERT nes and pBabe-puro GFPhTERT nes 
were sequenced to verify their identities. The double mutant can’t be 
displayed in one strip because the mutations are separated by 262 bases.
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Creation of 293 GFPhTERT and mutants cell lines 
 The following vectors: pBabe puro control, pBabe-puro GFPhTERT, pBabe-puro 
GFP-DNhTERT D712A V713I, pBabe-puro GFP-DNhTERT D712A V713I nes and 
pBabe-puro GFPhTERT nes were co-transfected with pCL ampho, the packaging 
plasmid, and pME VSVg, the envelope plasmid, into the viral packaging cell line, 293T. 
Retroviruses were used to infect 293, a human embryonic kidney cell line immortalized 
with the gene products, E1a and E1b of adenovirus 5. These cells were used because 
exhaustive preliminary tests among different cell lines showed the 293 cells to be better 
at expressing the various constructs. Its disadvantage was the difficulty in fixation and 
immunostaining the cells. After selection for 1 week with 700 ng/ml of puromycin, a 
mass population of each construct was created and characterized.  
 
Telomeres shorten with decreased fluorescence and protein in 293 GFPDNhTERT  
To determine the effects of the dominant-negative mutation and/or nuclear export 
signal mutattion on hTERT levels and telomere length, confocal imaging, western blot 
and telomere length analysis were performed on each cell line. The mean telomere length 
of 293 GFPhTERT cells was increased to 5.5 kb as compared to the 3.5 kb in 293 pBabe 
control cells (Figure 28). Dominant-negative expression alone or in combination with the 
nuclear export signal mutant caused a reduction to 2.7 and 2.5 kb, respectively. The nes 
mutant caused a slight reduction to 3.2 kb. GFP-DNhTERT showed a decrease in 
fluorescence intensity and protein level as compared to the wild type (Figure 29). Upon 
closer inspection, the remaining GFP-DNhTERT have aggregated within the nucleus. Co- 
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293       wt      DN       DN       nes    
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12---
10---
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Mean telomere length: 3.5   5.5    2.7   2.5    3.2    kb
Figure 28. Dominant negative hTERT (D712A V713I) causes shortening of 
telomeres even in combination with the nuclear exportation signal 
mutation. 293 pBabe, 293 GFPhTERT, 293 GFPDNhTERT, 293 GFP-
DNhTERT nes and 293 GFPhTERT nes. 2.5 µg of genomic DNA was 
hybridized with radioactive telomeric probe in solution and processed according 
to the TALA protocol.
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293 GFP-DNhTERT293 GFPhTERT 293 GFP-DNhTERT-nes
293 pBabe293 GFPhTERT nes 293 GFP
293              wt                DN              DN         nes   
pBabe                                                    nes 
GFPhTERT
β -actin
Figure 29. Correlation between fluorescence and protein levels in 293 
expressing wild-type and mutant GFPhTERTs. 293 GFP-DNhTERT shows 
diminished fluorescence and protein level as compared to the wild-type control 
of 293 GFPhTERT. The double mutant of DNhTERT nes shows the recovery of 
fluorescence and protein level. Live cell imaging performed on a Leica confocal
microscope. Western analysis probed with anti-hTERT from Rockland Inc. 
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localization studies showed that these GFPDNhTERT translocated to nucleoli (Figure 30 
lower panel) as compared to the lack there of for the 293 GFPhTERT cells (Figure 30 top 
panel). The additional mutation of the nuclear export signal is able to return the 
fluorescence intensity and protein level to that of wild-type; however, aggregates still 
formed in the nucleus (Figure 29). The nes mutation alone did not change the 
fluorescence nor protein level as compared to the wild-type. Surprisingly, this mutant did 
show an increase in cytoplasmic fluorescence as well as inconsistent results with prior 
infection and analysis. Taken together, these data suggest that D712A V713I mutation 
cause the DNhTERT to be exported to the cytoplasm for degradation as well as 
translocation to the nucleoli for sequestration. The nes mutation is able to prevent this 
exportation and degradation yet its expression alone causes contradictory results.  
 
Creation of Lentiviral CMV based vectors and their expression in 293 cells 
 With inconclusive data about the potential cytoplasmic degradation of DNhTERT, 
the effects of the dominant-negative mutation were further explored through a lentiviral 
based vector that utilized a CMV promoter. GFPhTERT and mutants were subcloned 
from the pBabe retroviral vectors into the pHR CMV lentiviral vectors. Restriction 
analysis and DNA sequencing was used to verify each construct. Lentiviruses were made 
and infected into 293 cells. Following puromycin selection, whole populations of cells for 
each vector were characterized.   
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GFPhTERT merged nucleoli
GFPDNhTERT merged nucleoli
Figure 30. Only 293 GFPDNhTERT co-localize with the nucleoli. Cells 
were immunostained with the fibrillarin antibody (Santa Cruz sc-25397). Anti-
rabbit secondary antibody was Alexa Fluor 647 (Invitrogen A21245). Scale bar 
is 28 µm.
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Cytoplasmic degradation of CMV driven GFPDNhTERT in 293 cells 
To confirm that these lentivectors were functional, telomere length analysis 
showed an increased to 5.0 kb for 293 CMV GFPhTERT as compared to the 3.2 kb for 
293 CMV GFP (Figure 31A). The dominant-negative (DN) version reduced the telomere 
length to 2.5 kb. Confocal microscopy analysis showed mostly nuclear fluorescence and 
some aggregation with the highly over-expressed wild-type (WT) hTERT (Figure 31B). 
For the dominant negative, the fluorescence intensity decreased more dramatically along 
with the appearance of cytoplasmic aggregation and lack of translocation to the nucleoli 
when compared to 293 GFPDNhTERT (Figure 30 lower panel). Unforturnately, we were 
unable to detect a co-localization between GFPDNhTERT and the proteasome (Figure 
32). This may be due to complete degradation of GFPDNhTERT such that inhibition of 
proteasomes does not lead to aggregation. Future studies can be conducted at earlier time 
points beginning with 1 day after infection of the lentivirus. Western blot and semi-
quantitative RT-PCR analysis showed a decreased in protein level yet similar RNA levels 
of the DN as compared to the WT (Figure 33). In addition, the endogenous mRNA levels 
of hTERT appear to decrease and increase with over-expression of the exogenous WT 
and DN version of GFPhTERT, respectively, as compared to the control of 293 CMV 
GFP. However, more quantitative assays need to be done.  
 To determine if the DN was being degraded, 293 CMV GFPDNhTERT cells were 
exposed for 6 hours to the proteasome inhibitor, MG132. There was an increase in GFP-
DNhTERT protein level as compared to the DMSO treated cells but not to the same level 
as the WT (Figure 34). Furthermore, the DN was treated for 6  
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293 CMV  GFP
293 CMV  GFPhTERT
293 CMV  GFP-DNhTERT
Figure 31. Dominant-negative hTERT shortens telomeres and aggregates in 
the cytoplasm. A. Lane 1 : 293 CMV GFP, Lane 2 : 293 CMV GFPhTERT and 
Lane 3: 293 CMV GFPDNhTERT (D712A V713I).  The mean telomere length 
is quantitated at the bottom. B. Confocal live cell imaging show changes in 
intensity and location of the fluorescence between wild-type and dominant-
negative hTERT.
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GFPhTERT MG132 merged proteasome
GFPDNhTERT MG132 merged proteasome
Figure 32. 293 CMV GFPDNhTERT does not co-localize with proteasome.
Cells were immunostained with the 20S antibody (BIOMOL PW8155). Anti-
rabbit secondary antibody was Alexa Fluor 647 (Invitrogen A21245). Scale bar 
is 42.54 µm for top panel and 25.43 µm for bottom panel. In order to be able to 
fix 293 cells properly, 40% paraformaldehyde at pH 7.4 must be applied 
directly onto cells growing in complete media without prior PBS wash. Add 
appropriate volume so that final concentration is 4% paraformaldehyde then 
follow immunostaining procedure. Cells must be grown on 1% gelatin so that 
washing step doesn’t cause loss of specimens.
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293 CMV 
GFP
293 CMV
GFPhTERT
293 CMV 
GFPDNhTERT
Exo hTERT
β -actin
Endo hTERT
Exo hTERT
18S
Figure 33. Dominant-negative hTERT’s lower protein level associated with 
higher endogenous hTERT mRNA. In contrast, high exogenous wild-type 
GFPhTERT protein levels may lower endogenous hTERT mRNA. Even with 
equal RNA levels of exogenous hTERT, the DNhTERT has lower levels of 
protein. Western analysis probed with anti-hTERT from Rockland Inc. Semi-
quantitative RT-PCR used to assess changes in mRNA levels. 
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A 293 CMV GFPDNhTERT293 CMV
GFPhTERT
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Exo hTERT
β -actin
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293 CMV
GFP
WT DN WT DN
lysate MG132 MG132DMSO DMSO
130 kD
180 kD
Figure 34. Dominant-negative hTERT is ubiquinated, exported and 
degraded. A. 293 CMV GFPDNhTERT was pre-treated for 6 hours with 
DMSO, 10 µM MG132, 100 nM LMB before lysis. Western analysis probed 
with anti-hTERT from Rockland Inc. B. 293 CMV GFPhTERT and 293 CMV 
GFPDNhTERT were pre-treated for 6 hours with 10 µM MG132. Cells were 
lysed and immunoprecipitated with rabbit GFP antibodies. Western blot 
analysis used monoclonal mouse anti-ubiquitin. 293 CMV GFPhTERT lysate 
and 293 CMV GFP immunoprecipitate served as the positive and negative 
control, respectively.
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hours with the nuclear exportation inhibitor, Leptomycin B, which increased the protein 
level to a lesser extent than the MG132-treated cells. To confirm that the dominant 
negative was being degraded, its ubiquination status was determined with 
immunoprecipitation by GFP antibodies followed by Western analysis for ubiquitin. The 
poly-ubiquinated protein usually appears as high molecular weight smears and is 
diagnostic of a protein marked for proteasomal degradation The dominant-negative 
showed an increase in ubiquitination as compared to the wild-types, both in the DMSO 
and MG132-treated cells. In comparing wild-type treated with MG132 vs. DMSO, the 
data showed that blocking hTERT normal turnover resulted in more ubiquinated hTERT 
being observed. In order to obtain enough protein before complete degradation  even with 
proteasome inhibition for these assays, it was sometime necessary to harvest cells 1 to 2 
days after infection. Taken together, these data suggest that DNhTERT is ubiquinated and 
exported for cytoplasmic degradation. 
 
Creation of P69 GFPhTERT hygro CMV hTERT or DNhTERT puro 
 In trying to understand the mechanism of dominant-negative hTERT and its effect 
on wild-type telomerase and vise versa, we over-expressed both in the P69 cell line. 
hTERT and DNhTERT without the N-terminal GFP tag were subcloned from their 
respective pBabe-puro vectors into the pHR CMV ires puro vector. Restriction analysis 
and DNA sequencing was used to verify each construct. Lentiviruses were made and 
infected into P69 GFPhTERT hygro. After selection with puromycin, populations of cells 
were analyzed for telomere length, fluorescence, hTERT protein and RNA level. 
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DNhTERT causes degradation of WT hTERT 
  Immunoblot analysis showed a decrease in the protein level of wild type hTERT 
after expression of the DNhTERT, which was at an even lower level (Figure 35). This 
decrease was not due to a change in RNA levels because semi-quantitative RT-PCR 
analysis showed no difference in exogenous GFPhTERT and hTERT between P69 
GFPhTERT & hTERT and P69 GFPhTERT & DNhTERT. In addition, the fluorescence 
intensity decreased to 66% of control with expression of the DNhTERT (Figure 36). The 
co-expression of wild-type hTERT caused no change in the protein level or fluorescence 
of the GFPhTERT (Figure 35 and 36). In contrast to these changes, the expression of 
DNhTERT was not able to shorten the extended telomeres of the P69 GFPhTERT 
(Figure 37). Additionally, the further increase in wild-type hTERT in the P69 
GFPhTERT & hTERT cells caused no significant changes in the mean telomere length. 
Finally, the protein level of GFPhTERT and DNhTERT increased after 6 hours of 
treatment with the proteasome inhibtor, MG132 and to a lesser extent, with the nuclear 
exportation inhibitor, Leptomycin B (Figure 38). However, neither treatment was able to 
restore the level of GFPhTERT to that of P69 GFPhTERT. The DMSO control and the 
puromycin control showed no significant changes. Taken together, these data suggest that 
the dominant-negative causes the cytoplasmic degradation of the wild-type hTERT at the 
protein level. In addition, if wild-type telomerase is not reduced by DNhTERT to 
undetectable levels, then telomeres may not shorten.    
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Figure 35. Dominant-negative hTERT reduces protein levels of wild-type 
hTERT. P69 cells are expressing GFPhTERT under hygromycin selection and 
hTERT or DNhTERT under puromycin selection. Western blot probed with 
anti-hTERT from Rockland Inc.  Semi-quantitative RT-PCR used to analyze 
mRNA levels.
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Figure 36. Dominant-negative hTERT reduces the fluorescence intensity of 
wild-type GFPhTERT. Three samples of approximately equal cellular density 
were taken for each condition. Fluorescence measured immediately after 
selection. Scale bar is 75 µm.
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Figure 37. Reduced levels of wild-type GFPhTERT still maintain extended 
telomeres. Lane 1: P69 pBabe control, Lane 2: P69 GFPhTERT, Lane 3: P69 
GFPhTERT & pHR control, Lane 4: P69 GFPhTERT & hTERT, Lane 5: P69 
GFPhTERT & DNhTERT. Mean telomere length is quantitated at the bottom.  
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P69
GFP-
hTERT
P69 GFPhTERT& DNhTERT
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GFPhTERT
DNhTERT
β -actin
Figure 38. Exogenous GFPhTERT and DNhTERT are exported and 
degraded in the cytoplasm. P69 cells are expressing GFPhTERT under 
hygromycin selection and hTERT or DNhTERT under puromycin selection. 
Cells was pre-treated for 6 hours with DMSO, 10 µM MG132, 100 nM LMB 
before lysis. Western blot probed with anti-hTERT from Rockland Inc and B-
actin from Sigma. 
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Chapter 5 
Discussion 
 
 
Overall, we have shown that telomerase can be degraded in the nucleoplasm or 
cytoplasm depending on the mechanism of inhibition. The significance of this is a better 
understanding of how Hsp90 inhibition and dominant negative hTERT expression cause 
the degradation of wild-type hTERT. With this knowledge, future drug therapies can be 
designed based on these inhibitors to not only inactivate but also to cause the degradation 
of an enzyme that is crucially important for the immortalization of cancer cells. 
 
Nuclear Degradation 
 Hsp90 inhibition has been shown to cause the degradation of telomerase. In this 
study, we show that telomerase can be induced towards nuclear degradation with the 
Hsp90 inhibitor, Radicicol. Specifically, un-assembled hTERT complexed with Hsp90 is 
degraded in the nucleus within 2 hours; in contrast to the 24 hours it takes to decrease 
activity of assembled telomerase upon exposure to Radicicol. A nuclear exportation 
inhibitor, Leptomycin B, is not able to prevent this degradation. However, the proteasome 
inhibitor,  MG132, not only prevent this degradation but causes telomerase to aggregate 
with the proteasome in the nucleoplasm excluding the nucleoli.  
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 Our overall model for the Hsp90 inhibition induced degradation of telomerase is 
based on hTERT in different states of assembly and complexes. Un-assembled but folded 
hTERT is complexed to Hsp90 without p23 thus allowing Radicicol to easily bind and 
cause the immediate nuclear degradation. For the active assembled telomerase complexed 
with Hsp90 and p23, there is a relatively delayed effect because the inhibitor has to break 
the cycle of the complex binding to, dissociation from and then translocation on the 
telomere. When the complex is associated with p23, telomerase is not bound to the 
telomere but also not susceptible to Radicicol. As p23 dissociate from the complex, 
Hsp90 completes an ATPase cycle and telomerase is able to bind the telomere. Within 
this timeframe, there is a window of opportunity for Radicicol to out-compete the next 
ATP for binding the N-terminus of Hsp90 and prevent the start of the next ATPase cycle 
and telomerase-telomere elongation cycle. Upon inhibition, the complex of hTERT, hTR 
and Hsp90 may be degraded in the nucleus as well, because Hsp90 is not able to 
dissociate thus making it more prone to ubiquination by an E3 ligase that may associate 
with the C-terminus of Hsp90. Once ubiquinated, the un-assembled hTERT and 
assembled telomerase with their non-dissociating Hsp90 are sent to the nuclear 
proteasomes to be degraded.   
 Proteasomes have been shown to exist in the nucleus and cytoplasm. Nuclear 
degradation has been discovered for many proteins and serves several purposes but most 
obviously is the quality control of nuclear protein that are damaged, misfolded or 
accumulated in inclusion bodies (von Mikecz 2006). For Hsp90 inhibition, this type of 
induced degradation for telomerase appears to occur in the nucleus. The reason for this 
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may be that Radicicol binding to the N-terminal ATP binding pocket of Hsp90 causes the 
chaperone dimer to remain associated with its client protein, making it more prone to 
ubiquination. Although Kim et al showed that telomerase is ubiquinated by an E3 ligase 
called MKRN1, they didn’t exclude the possibility that geldanamycin induced 
degradation may cause ubiquination by another E3 ligase called C-terminal Hsc-70 
interacting protein (CHIP). Connell et al showed that CHIP can switch Hsp90 from 
protein folding to degradation with Geldanamycin treatment (Connell et al. 2001). Even 
though CHIP tagged with GFP is reported to be cytoplasmic (Ballinger et al. 1999), its 
own low molecular weight of approximately 33 kDa may allow it to freely traverse the 
nuclear membrane. It could also be imported with appropriate stimuli since it contains 
two potential nuclear localization signals. Therefore, we think that Hsp90 inhibition by 
Radicicol causes the chaperone dimer to remain associated with hTERT thereby giving 
more opportunities for an ubiquitin ligase to poly-ubiquinate telomerase thus causing 
immediate nuclear degradation. Determining whether MKRN1 or CHIP plays this role 
could be a topic for future studies. 
In addition, the choice of nuclear verses cytoplasmic degradation may depend on 
other factors. For example, the amount of ubiquination has been shown to regulate the 
location of p53 degradation. This enzyme is degraded in the cytoplasm if it is 
monoubiquinated and in the nucleus if it is poly-ubiquinated (Li et al. 2003). Another 
possibility is that the sudden presence of large amounts ubiquitinated proteins in the 
nucleus after Hsp90 inhibition requires immediate degradation to reduce the possibility of 
these damaged proteins interfering with nuclear functions. In this context, some 
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ubiquinated hTERT may be exported to the cytoplasm but may overwhelm the limiting 
amount of the exportation machinery of CRM1 and Ran GTPase.  
  Even though we show that telomerase aggregate with proteasomes in the 
nucleoplasm exclusively, it may aggregate with other proteins such as chaperones and 
ubiquitin. All of which may be part of nuclear proteolytic centers as suggested in some 
cases for PML (promyelocytic leukemia) nuclear bodies (Anton et al. 1999; Rockel et al. 
2005). In contrast, we also showed that when the proteasome is inhibited alone with 
MG132, telomerase aggregate or translocate next to nucleoli. We think that MG132-
induced translocation is a stress response similar to the genotoxic stress response of 
irradiation. Inhibition of degradation is a very stressful state causing almost every cell to 
begin to die after 8-12 hours of treatment. Finally, aggregation to within the nucleoli 
supports the concept that access to the GFPhTERT is required for signaling of 
degradation by ubiquination. GFPhTERT were stimulated to translocate to the nucleoli 
with DNA damage from hydrogen peroxide before inducing degradation. In doing so, we 
are able to reduce the level of degradation from Hsp90 inhibition.   
 Overexpression of exogenous telomerase produces protein levels that are much 
higher than that of endogenous and could therefore affect the results. It is possible that 
much of the exogenous GFPhTERT is not assembled as a ribonucleoprotein and remains 
in the nucleoplasm as a client protein bound to various chaperones including Hsp90 and 
p23. Within this scenario, two possible reasons include 1) the cell’s ability to sense the 
lack of a need to assemble more ribonucleoprotein and 2) the limiting amount of hTR 
available as compared to the overexpressed GFPhTERT. So it is possible that most of the 
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observed nuclear degradation occurred with unassembled GFPhTERT. This could explain 
our discordant result of telomerase activity remaining the same after 6 hours of Radicicol 
treatment while causing an 80-90% reduction of protein in the P69 GFPhTERT cell line. 
Therefore, we propose that overexpression of exogenous hTERT creates two unequal 
pools of enzymes consisting mostly of unassembled GFPhTERT bound to Hsp90; and 
assembled GFPhTERT : hTR bound by Hsp90 and p23. In application towards tumor 
cells, it is possible that reactivation of telomerase creates a pool of un-assembled hTERT 
bound to Hsp90 to facilitate quick assembly of the ribonucleoprotein as needed and to 
provide additional regulation of its activity. 
To determine the reason for the difference in the activity and protein levels, a 
couple of experiments can be conducted. First, higher concentrations of Hsp90 inhibitors 
may be needed to decrease activity. As shown by Keppler at al, 53 µM of geldanmycin 
was needed to inhibit activity verses 8.4 µM for assembly. Therefore, future studies 
should generate an activity-dosage response curve with Radicicol concentration ranging 
from 0.5 to 10 µM and treatment for 6 hours.  Another reason for this disparity in activity 
and protein levels may be due to different pools of un-assembled and assembled 
telomerase. This concept can be tested by measuring the hTR levels before and after 
Hsp90 inhibition. An example would be an IP for GFPhTERT followed by a quantitative 
or real-time RT-PCR assay for hTR comparing before and after 0.5 µM Radicicol 
treatment. If un-assembled GFPhTERT is degraded, then more active assembled 
GFPhTERT with hTR can competitively bind to the antibodies resulting in the 
paradoxical detection of more hTR after Radicicol treatment. 
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Recent development in the field has suggested the possibility of assembled 
telomerase not in complex with chaperones. (Mizuno et al. 2007) showed that telomerase 
exists as two active complexes with a molecular mass of 380 kDa and 680 kDa . The 
larger complex of 680 kDa had been characterized by Cohen et al to be composed of 
dimers of hTERT (127 kDa), hTR (153 kDa) and dyskerin (57 kDa) (Cohen et al. 2007). 
The 380 kDA complex is believed to be composed of hTERT, hTR and Hsp90. However, 
Hsp90 functions as a dimer with 2 co-chaperone p23 when bound to client proteins. The 
combined mass of hsp90 dimer, hTERT and hTR equals 450 kDa or 500 kDa with the 
p23s while that of hTERT, hTR and dyskerin equals 340 kDa. With this discrepancy in 
molecular weight, the composition of the 380 kDa complex needs to be further tested. 
Our data supports this concept of assembled telomerase transiently complexed with 
chaperones in that it took 24 hours to cause a decrease in activity while 2-3 hours to 
cause a decrease in fluorescence and protein level. The delayed inhibition of assembled 
telomerase suggests it is not associated with chaperones most of the time and if so only 
transiently. It is during these brief periods that the assembled telomerase is vulnerable to 
chaperone inhibitors. In a larger perspective, the possible reasons for assembled 
telomerase’s transient binding to the Hsp90 and p23 are to promote DNA binding and 
nucleotide addition properties, thus illustrating the need for chaperones to possibly 
change the ribonucleoprotein’s conformation to bind and release from the telomere 
(Toogun et al. 2007; Toogun et al. 2008). 
To answer the question as to whether nuclear degradation occurs with the 
endogenous telomerase, future studies should be conducted using cell lines shown to 
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have detectable endogenous telomerase on immunofluorescence and relatively high 
telomerase protein level. These may include the promyelocytic leukemia cell line, NB4-
LR1, (Wu et al. 2006); the lung carcinoma cell line, H1299, (Kim et al. 2005); the human 
embryonic kidney cell line, 293, (Cohen et al. 2007); and the cervical carcinoma cell line, 
HELA, (Savre-Train et al. 2000). The polyclonal rabbit antibody to hTERT from 
Rockland Inc should be used for both Western and IF analysis. This antibody, in our 
hands and according to Wu et al., seems to be the best commercially available antibody. 
To increase its efficacy and reduce variability, one could produce monoclonal antibodies 
based on the same C-terminus peptide antigen spanning amino acids 1104-1123: SRK 
LPG TTL TAL EAA ANP AL. 
 
Clinical application and future pharmacological development 
 
  We want to address a more clinically relevant issue involving the Hsp90 inhibitor 
in clinical trials at the present time, 17-allyamino-17demethoxy-geldanamycin (17-
AAG). Phase I results for this drug show that effective dosages can be achieved without 
toxicity in advanced cancer patients and can proceed to Phase II (Solit et al. 2007). 
Although it may cause the nuclear degradation of telomerase in these patients’ cancer 
cells, it may also cause its cytoplasmic client proteins to undergo cytoplasmic 
degradation. For example, the glucocorticoid receptor is cytoplasmic until it binds its 
ligand. Treatment would most likely cause its immediate degradation in the cytoplasm. 
Even though this drug has some clinical potential, the likelihood of resistance and 
toxicity is foreseeable. Future research should try to elucidate specific regions of 
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telomerase that interact with Hsp90 so that drugs could someday be designed with the 
specificity towards telomerase combine with the degradation effects of Hsp90 inhibition. 
 An intermediate approach to allow for more specificity of the Hsp90 inhibitor is 
to limit the delivery of 17-AAG to the nucleus by targeted charge-reversal nanoparticles. 
The concept is similar to the transfection of cells in culture but modified and enhanced so 
that drugs can be delivered to tumors more effectively, in vivo. Xu et al, 2007 show that a 
negatively charged nanoparticle can utilize the low pH of endosomes to convert it to 
become positively charged and thus traverse the cell more easily to deliver the drug to the 
nucleus (Xu et al. 2007). This system has several other benefits including: preferential 
uptake by cancerous tissue due to the enhanced permeation and retention effect and use 
of active targeting such as folate conjugation, the initial negative charge state allowing 
little interaction with the blood components, and the positive charge state allowing 
movement on molecular motors along the microtubules. Finally, releasing the drug into 
the nucleus not only bypass the multi-drug resistance mechanism in the cell membrane 
but for our purposes, reduce the side effect of inhibiting hsp90 in the cytoplasm where 
most of the chaperone’s activity occurs. Utilization of this carrier also negates the initial 
pharmacokinetic issues such that any hsp90 inhibitor may be used. 
 With any pharmacological inhibitor of telomerase, the end goal is to have the 
clinical result of slowing the growth or inducing the apoptosis of the primary tumor and 
its metastases. To this end, rational drug design is the preferred path however it requires 
the crystal structure of the target protein. Recently, the crystal structure of the Tribolium 
Casteneum catalytic subunit of telomerase was solved and has features similar to that of 
 92
the retroviral reverse transcriptases, viral RNA polymerases and B-family DNA 
polymerases (Gillis et al. 2008). Even though human telomerase has a primary sequence 
homology of 23% and contains a TEN domain, it is expected that the spatial homology 
with T. casteneum TERT will still allow the crystal structure to serve as a model for the 
rational design of novel pharmacological inhibitors. Comparative modeling may help to 
find a binding pocket in the reverse transcriptase domains that is similar to that for the 
non-nucleoside reverse transcriptase inhibitor, e.g. efavirenz and nevirapine, of HIV-1. 
There are many other potential sub-targets since hTERT has several other 
domains that are non-existent for HIV such as TEN, TRBD and C-terminal domains. For 
example, the TEN domain of T. thermophila has surface exposed conserved amino acids 
in a groove that are critical for telomerase activity because they are required for binding 
the single stranded telomeric DNA (Jacobs et al. 2006). The TRBD binding domain has a 
T pocket or motif that have surface exposed conserved amino acids involved in single 
stranded RNA binding (Rouda and Skordalakes 2007). The C-terminal domain has a 
thumb loop involved in DNA binding and elongated helical bundles that interact with the 
TRBD domain to create a tertiary ring-like structure (Gillis et al. 2008). Since mutation at 
these sites and C-terminal tags cause severe loss of activity, it is reasonable to assume 
that developing drugs to bind to these areas should also inhibit telomerase activity. 
However, comparative modeling of these domains to predict the human telomerase may 
prove to be difficult because not only do these domains have novel protein folds, there 
are only 1-2 known crystal structure of these domains.  
Therefore, the acquisition of the crystal structure of human telomerase still 
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remains a scientific and therapeutic necessity. In order to form crystals, the process must 
start with obtaining enough protein at a purity of 99% so that crystallization can be 
attempted at many different conditions. This requirement has been very frustrating to 
numerous investigators who have utilized different tags such as Flag and GST and 
expression system such as yeast and insect cells. Our initial attempts at using a self-
cleavable tag called intein along with a chitin binding domain expressed in yeasts have 
been unsuccessful. Other than trying different tags and other species of yeast, it may be 
necessary to express and purify hTERT in human cell lines so as to avoid these problems. 
The cost of such an endeavor maybe prohibitive but can be reduced if one uses the 293T 
cell line which can grow in suspension and with bovine calf serum.  
 
Cytoplasmic Degradation and Mechanism of Dominant Negative hTERT 
In this study, we showed that the dominant negative mutation (D712A V713I) not 
only causes the cytoplasmic degradation of the mutant hTERT but also of the wild-type 
hTERT. This may be one of the mechanisms of how DNhTERT expression effects the 
endogenous telomerase, thus leading to a decrease in catalytic activity, shortening of the 
telomeres and eventually senescence or apoptosis of the cancer cell. In addition, we have 
not rule out the possibility that expression of DNhTERT can cause the cell to undergo 
quiescence which has been shown to reduce telomerase activity (Holt et al. 1999). 
However, the protein samples and fluorescence images taken during the continuous 
growth of 293 GFPDNhTERT and P69 GFPhTERT DNhTERT suggested that temporary 
or permanent growth arrest did not play a role in the degradation. To confirm this 
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possibility, future studies can measure the fluorescence and protein levels as well as the 
beta-galactose senescence stain after treating 293 GFPhTERT or P69 GFPhTERT with 
high dose irradiation or serum starvation.  
Further analysis of these results supports the theory of telomerase dimerization 
and functional interaction between the monomers. If telomerase function as a monomer, 
then degradation of the mutant monomer should not affect the wild-type monomer. 
However, the result from Figure 35 suggests a model in which a heterodimer of wt 
hTERT and DN hTERT being more prone to degradation than a homodimer of wt 
hTERT. Furthermore, the homodimer of DNhTERT may be degraded even faster than a 
heterodimer of wt hTERT and DNhTERT. The reasoning being that P69 GFPhTERT & 
hTERT expressed an approximately equal amount of exogenous hTERT and GFPhTERT; 
however the P69 GFPhTERT & DNhTERT shows an unequal reduction of protein 
between the wild-type and the dominant negative. For example, if the heterodimer was 
not degraded faster than the homodimer of wt hTERT then there should be 1/3 of 
DNhTERT still present as compared to exo hTERT. However, the Western blot shows a 
much smaller amount than 1/3 for DNhTERT thus suggesting the unequal degradation 
pattern.  
In conjunction with the Western blot data, the telomere length analysis of the P69 
cell line expressing both GFPhTERT and DNhTERT shown in Figure 37 suggest a need 
to refine the definition of the dominant negative effect for telomerase. By definition, the 
DNhTERT should dominate over the GFPhTERT and cause a shortening of the 
telomeres. However, quantitative analysis of the telomeres shows no significant 
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difference between P69 GFPhTERT and P69 GFPhTERT & DNhTERT. This result can 
be explained by the Western blot showing a reduced but still higher level of active 
GFPhTERT than the DNhTERT. Therefore the concept of a dominant negative effect has 
to be limited to the situation in which its overexpression overwhelms the endogenous low 
protein levels of wild-type to cause telomere shortening. Co-overexpression of wild-type 
negates the dominant negative effect for telomerase.  
Another interesting observation is that varying degrees of overexpression of wild-
type telomerase cause the same level of telomere extension. As shown in Figures 35 and 
37, quantitative telomere length analysis shows no significant difference between P69 
GFPhTERT vs. P69 GFPhTERT & hTERT vs. P69 GFPhTERT & DNhTERT yet their 
protein level of wild type hTERT vary from medium to high to low, relatively and 
respectively. This supports the concept that telomeres can only be extended to a certain 
limit that may be based on the formation a telomere T loop that serves as a feedback 
inhibition to prevent further lengthening (Griffith et al. 1999). It is also possible that the 
low level of wild type hTERT in P69 GFPhTERT & DNhTERT has already saturated the 
limiting amount of hTR or some other components to form active assembled telomerase.  
In addition to the cytoplasmic degradation, there is an initial aggregation of the 
dominant negative telomerase to the nucleoli in live cell of 293 GFPDNhTERT. 
Confirming this is the co-localization of GFPDNhTERT with fibrillarin as compared to 
the lack there of in 293 GFPhTERT. This suggests the possibility that the dominant 
negative may cause a DNA damage response similar to the irradiation response of 
nucleolar translocation (Wong et al. 2002). Another possibility is that DNhTERT cause 
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the loss of the 3’overhang which may result in the uncapping of the telomeres thus 
generating a DNA damage response (Masutomi et al. 2003). In terms of degradation, the 
translocation of GFPDNhTERT to the nucleoli may reduce its destruction by the 
proteasome which has been shown to be unable to access the nucleoli (von Mikecz 2006). 
Another potential mechanism for the dominant negative effect is the sequestration 
of the heterodimer DNhTERT : wt hTERT to the nucleoli. This is exemplified by the 
result showing that a mutation for the nuclear export signal (nes) being able to prevent 
the exportation and degradation of the dominant negative mutant yet still cause the 
shortening of the telomeres. This double mutant also has nuclear aggregation similar to 
the DNhTERT mutant alone and suggests that sequestration of the heterodimer may 
reduce the availability of wt hTERT in the nucleoplasm and its access to the telomere. 
 Since the 26S proteasome has been shown to exist in the nucleus along with all 
the ubiquination cycle enzymes of degradation, one has to wonder why the double mutant 
needs to be degraded in the cytoplasm. One hypothetical explanation is that certain 
chaperones or proteins that function to monitor the proteome may exist predominantly in 
the cytoplasm and translocate to the nucleus with specific stimulation such as CHIP  
(Ballinger et al. 1999). Another possibility is that the DNhTERT is only marked for 
exportation in the nucleus and then tagged for degradation by ubiquination in the 
cytoplasm. Beyond these speculations, the results for the double mutant need to be 
repeated. 
 Two additional topics that need to be addressed involve the dominant negative 
mutant alone and the nes mutant alone. We have only shown the degradation of 
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exogenous wild-type hTERT by the DNhTERT. Future studies need to show the 
degradation of endogenous hTERT after DNhTERT expression which can be conducted 
in cancer cells shown to have relatively high hTERT protein levels. As for the 
inconsistent results of the nes mutant having increased cytoplasmic localization, it is 
possible that long term prevention of the natural translocation of protein may induce 
cellular stress that cause the exportation of hTERT by an unknown CRM1-independent 
mechanism. These other exportation mechanisms have been shown for numerous proteins  
(Vajjhala et al. 2003; Kindsmuller et al. 2007). 
 Instead of being exported for degradation, it is possible that the DNhTERT is 
ubiquinated and degraded in the cytoplasm soon after translation. This scenario allows 
for another possibility in which DNhTERT is not imported into the nucleus and 
prevented from heterodimerization with wt hTERT. The cancer cells can eventually gains 
resistance to the DNhTERT even though there are high levels of the dominant negative 
transcript. Thus, we propose a new mechanism of resistance, which is the degradation of 
DNhTERT protein before its nuclear importation. Resistances to the dominant negative 
effect have been documented with data showing some clones losing the mutant transgene 
while other clones continue to express it (Delhommeau et al. 2002). Resistance despite 
continued expression of the transgene could either be due to the new mechanism 
proposed or the amplification of the endogenous mRNA. 
   In this study, we have only shown the dominant negative effect for the D712A 
V713I mutant and proposed two mechanisms by which this may occur. A natural 
extension of this study is to investigate the other Aspartate mutants in this triad: D868 
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and D869. The theory of cofactor catalysis by two divalent metal cations has not been 
fully investigated. Additionally, it is unknown as to whether these Aspartate mutants will 
cause the degradation of the mutant and the wild-type hTERT. We have preliminary 
evidence that suggests the D712A mutation is the only mutant that causes degradation 
and a significant shortening of the telomeres. The other Aspartate mutants have protein 
levels similar to wild-type as shown by Western analysis. These D868A and D869A 
mutants did not cause the initial nucleoli localization followed by a cytoplasmic 
distribution like that of D712A. Their telomeres remain the same or did not shorten 
significantly as compared to the D712A mutant. Review of the literature has shown that 
most of the papers showing a dominant negative effect utilize the D712A mutant. Despite 
the findings in these preliminary experiments, much more extensive testing needs to be 
conducted. Even if this is so, it brings up the question of why there is a difference. It 
could be that these Aspartates play different roles and thus different significance in 
catalysis which has been shown for the catalytic Aspartates of the HIV-1 reverse 
transcriptase (Kaushik et al. 1996).  
 
Post-translational Modification 
 
Another possible reason for the dominant negative effect is that only the D712A 
mutant disrupts a potential sumoylation site. Our preliminary studies of in vitro 
expression / post-translational modification did not show the presence or difference of 
SUMO1 attachment on the wild-type nor dominant negative hTERT.  The 
immunoprecipitation of GFPhTERT followed by Western analysis for SUMO had 
inconclusive data. Besides from optimizing the assay’s parameters, future studies can 
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address this hypothesis with an improved sumoylation assay using SUMO2 and SUMO3. 
If there is preliminary evidence to support the concept, then the creation of an K710R 
hTERT mutant can help in definitively proving the sumoylation site.  
Another post-translational modification that needs to be investigated is the 
potential phosphorylation of telomerase as suggested by the rapid translocation upon 
exposure to ionizing irradiation (Wong et al. 2002). Telomerase may be signaled by 
phosphorylation to translocate to the nucleoli in order to prevent it from adding telomeric 
repeats to newly created DNA ends due to double stranded breaks. The proposed 
phosphorylation cascade involves DNA damage recruiting repair proteins that result in 
the activation or phosphorylation of ATM or DNA-PK which phosphorylate and activate 
c-Abl which then phosphorylate and deactivate telomerase. To test this pathway, our 
preliminary finding shows Gleveec, a c-Abl inhibitor, preventing the translocation of 
telomerase upon 5 Gy irradiation. Gleevec or Imatinib is a synthetic tyrosine kinase 
inhibitor that has been shown to bind to the inactive conformation of the ATP binding 
domain of c-Abl thus explaining its high selectivity. Gleevec has also been shown by 
various labs to decrease telomerase activity which is contrary to the expected increase 
due to the inhibition of the c-Abl. This dichotomy may be due to Gleevec’s effect on 
other tyrosine kinases such as c-kit or PDGFR. This decrease in telomerase activity may 
be due to Akt dephosphorylation and hTERT mRNA downregulation (Uziel Lahav, 
2005). 
 At present, there are limited amount of information on the post-translational 
modification of telomerase such that many of the modified amino acid sites are unknown. 
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For example, the ubiquination of hTERT is only known to occur on some Lysine in the 
C-terminal domain by MKRN1. Other modifications such as the phosphorylation sites are 
unknown except for the Y707 shown by Haendeler et al. To identify these sites and to 
discover potentially new post-translational modifications such as sumoylation, the 
technique of liquid chromatography – electrospray ionization – quadrupole-time-of-flight  
tandem mass spectrometry (LC-ESI-q-TOF MS/MS) can be utilized in a similar manner 
as that employed for GAPDH (Seo et al. 2008). For example, GFPhTERT expressed in 
293 or P69 can be separated on 2D gel electrophoresis. The silver-stained gel spots is 
digested so that peptides can be analyzed in the LC-ESI-q-TOF MS/MS. Low abundant 
modifications can be enriched by excluding unmodified peptides in the final analysis. 
Certain modifications may be also enriched by exposing the cells expressing GFPhTERT 
to hsp90 inhibitors and proteasome inhibitors, inducing DNA damage and translocation 
with irradiation and hydrogen peroxide, and arresting the cell cycle with serum starvation 
and hydroxyurea. Determining the modified amino acids can contribute to a better 
understanding of how to develop drugs that not only inhibits its function but also 
modulate and activate telomerase as well.  
 
Therapeutic Application of DNhTERT 
 
 Applying the knowledge from a better understanding of the mechanism of 
dominant negative hTERT can also help to create drugs that inhibit telomerase in a 
similar fashion. For example, a drug that can block the acquisition of the magnesium ions 
cofactor in the catalytic domain can cause an inhibition of activity similar to effect of the 
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critical Aspartate mutants. If the post-translational modification of sumoylation is true, 
then preventing this change can lead to a translocation of the endogenous telomerase. A 
potential genetic therapy involves infection of tumor cells with DNhTERT from an 
adenovirus so that it can dimerize with the endogenous hTERT and induce the tumor 
cells to undergo apoptosis. The specificity of this method, due to the lack of endogenous 
hTERT in normal primary cells, is challenged by recent data that shows endogenous 
hTERT in the BJ fibroblast cell line (Masutomi et al. 2003). Our preliminary data does 
support this new theory in that expression of DNhTERT in BJ cells causes an early 
senescence phenotype. Another potential application of DNhTERT gene therapy is to 
generate more degradation products for presentation on MHC1 molecules so as to 
enhance the immunotherapy approach. This can remedy one of the limitations in this 
subfield by improving the education of immune surveillance cells such as macrophages 
and dendritic cells to telomerase which is reactivated in tumor cells but still expressed at 
a low copy number. This two-prong attack can not only cause the apoptosis of tumor cells 
but also potentially cause a longer lasting immunotherapy.    
  
Telomerase Cellular Trafficking 
The tools created through this research can be utilized to further study the cellular 
trafficking of telomerase. The wild type hTERT fused to GFP, originally a gift from Dr. 
Kathleen Collins, has been subcloned into various viral and non-viral vectors allowing 
for 3 types of antibiotic selection and different levels of expression and infectivity. In 
addition, various mutant versions are available as well as their combinations for the study 
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of telomerase’s translocation.   
At present, it is unknown as to how telomerase (assembled or unassembled) is 
transported from the cytoplasm after translation into the nucleus. Does telomerase 
randomly float around in the cytoplasm until some nuclear transporters recognize its 
nuclear localization signal? Or does telomerase utilizes the microtubulin retrograde 
transport system? Several Hsp90 client protein such as glucocorticoid receptor and p53 
are transported to the nucleus on microtubules via an adapter complex to dynein (Harrell 
et al. 2004) (Galigniana et al. 2004). This complex consists of immunophilin and 
dynamitin, serving as the link between the chaperones and dynein. Immunophilin has a 
peptidylprolylisomerase (PPIase) domain which binds immunosuppressant drugs, FK506 
and cyclosporine A. Overexpression of these components or exposure to the drugs block 
the retrograde transport by dissociating the motor protein from its cargo (Burkhardt et al. 
1997) (Galigniana et al. 2001). Similar experiments with the GFPhTERT can be 
performed to elucidate the mechanism of its nuclear importation. Preliminary data from 
the exposure to cyclosporine A and overexpression of PPIase or dynamitin are 
inconclusive and need further optimization of the materials and methods. The reward of 
understanding telomerase’s nuclear importation is obvious in that inhibition of this 
process prevents telomeres from being maintained by telomerase. 
 
In conclusion, the study of the degradation process for telomerase has been an 
important and revealing journey. We now have a better understanding of how the Hsp90 
inhibitors cause the immediate nuclear degradation of un-assembled telomerase and the 
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eventual inhibition of the assembled form’s activity. In addition, we propose new 
mechanisms for the effect of dominant negative telomerase by showing that the 
DNhTERT cause the exportation and cytoplasmic degradation of itself and endogenous 
wild-type telomerase. Finally, the application of this knowledge will allow us to design 
better cancer therapies that not only inhibit but also cause the degradation of an enzyme 
that is nearly universally required to maintain the cancer cell’s unlimited proliferative 
potential. 
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